


=>

Uploading C:\Program Files\Stnexp\Queries\10580872\azithromycin broad.str



chain nodes :

1 2 4 6 7 21

ring nodes :

3 5 8 9 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

1-15 2-11 4-9 5-7 6-10 20-21

ring bonds :

3-15 3-17 5-16 5-18 8-9 8-11 9-10 10-12 11-13 12-14 13-15 14-16 17-19
18-20 19-20

exact/norm bonds :

1-15 2-11 3-15 3-17 4-9 5-16 5-18 6-10 8-9 8-11 9-10 10-12 11-13 12-14
13-15 14-16 17-19 18-20 19-20 20-21

exact bonds :

5-7

Match level :

1:CLASS 2:CLASS 3:Atom 4:CLASS 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS

L5 STRUCTURE UPLOADED

=> s 15

SAMPLE SEARCH INITIATED 11:25:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 505 TO ITERATE

100.0% PROCESSED 505 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 8752 TO 11448

PROJECTED ANSWERS: 4998 TO 7082

L6 50 SEA SSS SAM L5

=> d his

(FILE 'HOME' ENTERED AT 11:10:54 ON 17 MAR 2010)

FILE 'REGISTRY' ENTERED AT 11:11:19 ON 17 MAR 2010
L1 1 S AZITHROMYCIN/CN

FILE 'REGISTRY' ENTERED AT 11:24:10 ON 17 MAR 2010
L2 STRUCTURE UPLOADED
L3 12 S L2
L4 261 S L3 FULL
L5 STRUCTURE UPLOADED
L6 50 S L5

=> s 15 full


FULL SEARCH INITIATED 11:25:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 9384 TO ITERATE

100.0% PROCESSED 9384 ITERATIONS 5538 ANSWERS
SEARCH TIME: 00.00.01

L7 5538 SEA SSS FUL L5

=>

Uploading C:\Program Files\Stnexp\Queries\10580872\azithromycin broad with c3.str



chain nodes :

1 2 4 6 7 21 28 29 30 31 32

ring nodes :

3 5 8 9 10 11 12 13 14 15 16 17 18 19 20 22 23 24 25 26 27

chain bonds :

1-15 2-11 2-22 4-9 5-7 6-10 20-21 24-28 25-29 26-30 26-31 31-32

ring bonds :

3-15 3-17 5-16 5-18 8-9 8-11 9-10 10-12 11-13 12-14 13-15 14-16 17-19
18-20 19-20 22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

1-15 2-11 2-22 3-15 3-17 4-9 5-16 5-18 6-10 8-9 8-11 9-10 10-12 11-13
12-14 13-15 14-16 17-19 18-20 19-20 20-21 22-23 22-27 23-24 24-25 25-26
25-29 26-27
26-31 31-32

exact bonds :

5-7 24-28 26-30

Match level :

1:CLASS 2:CLASS 3:Atom 4:CLASS 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS 29:CLASS 30:CLASS
31:CLASS
32:CLASS

=> s l16
SAMPLE SEARCH INITIATED 11:32:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 385 TO ITERATE

100.0% PROCESSED 385 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6523 TO 8877
PROJECTED ANSWERS: 4870 TO 6930

L17 50 SEA SSS SAM L16

=> s l16 full

L18 5333 SEA SSS FUL L16

=> l7 not l18
L20 205 L7 NOT L18


=> file caplus

=> s l20
L21 68 L20

=> d l21 1-68 ibib hitstr


L21 ANSWER 1 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1145902 CAPLUS <<LOGINID::20100317>>
TITLE: RP-HPLC determination of azithromycin and its related
substances in drug substances and parenteral
formulation
AUTHOR(S): Wang, Mingjuan; Xu, Mingzhe; Hu, Changqin; Wang,
Lixin; Wang, Chen
CORPORATE SOURCE: National Institute for the Control of Pharmaceutical
and Biological Products, Beijing, 100050, Peop. Rep.
China
SOURCE: Zhongguo Kangshengsu Zazhi (2008), 33(12), 740-745
CODEN: ZKZAEY; ISSN: 1001-8689
PUBLISHER: Zhongguo Kangshengsu Zazhishe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
IT **117693-41-1**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RP-HPLC determination of azithromycin and its related substances in drug
substances and parenteral formulation)
RN 117693-41-1 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 2 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1077656 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 151:367011
 TITLE: Aspects of degradation kinetics of azithromycin in aqueous solution
 AUTHOR(S): Zhang, Yu; Liu, Xiaoliang; Cui, Yue; Huang, Huifeng; Chi, Na; Tang, Xing
 CORPORATE SOURCE: Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, Peop. Rep. China
 SOURCE: Chromatographia (2009), 70(1/2), 67-73
 CODEN: CHRGB7; ISSN: 0009-5893
 PUBLISHER: Vieweg+Teubner Verlag/GWV Fachverlage GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT **117693-41-1**
 RL: ANT (Analyte); FMU (Formation, unclassified); PRP (Properties); ANST (Analytical study); FORM (Formation, nonpreparative)
 (aspects of degradation kinetics of azithromycin in aqueous solution)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:424084 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 151:41487
 TITLE: Development of a Topical Polymeric Mucoadhesive Ocular Delivery System for Azithromycin
 AUTHOR(S): Bowman, Lyle M.; Si, Erwin; Pang, Joseph; Archibald, Roy; Friedlaender, Mitchell
 CORPORATE SOURCE: Development and Operations, InSite Vision, Alameda, CA, USA
 SOURCE: Journal of Ocular Pharmacology and Therapeutics (2009), 25(2), 133-140
 CODEN: JOPTFU; ISSN: 1080-7683
 PUBLISHER: Mary Ann Liebert, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT **117693-41-1**
 RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)
 (development of topical polymeric mucoadhesive ocular delivery system for azithromycin)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 4 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:327077 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 150:495067
 TITLE: Total synthesis of azithromycin
 AUTHOR(S): Kim, Hyoung Cheul; Kang, Sung Ho
 CORPORATE SOURCE: Department of Chemistry, School of Molecular Science (BK21), KAIST, Daejeon, 305-701, S. Korea
 SOURCE: Angewandte Chemie, International Edition (2009), 48(10), 1827-1829
 CODEN: ACIEF5; ISSN: 1433-7851
 PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 150:495067


IT **1148112-31-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (total synthesis of azithromycin using chiral imine/CuCl₂ catalyst)

RN 1148112-31-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-ethyl-3,10,13-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 5 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:149756 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 150:168690

TITLE: Preparation of
9-deoxy-9A-methyl-9A-aza-9A-homo-erythromycin A
derivatives and their use for the treatment of malaria

INVENTOR(S): Alihodzic, Sulejman; Peric, Mihaela; Pesic, Dijana

PATENT ASSIGNEE(S): Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.,
Croatia

SOURCE: PCT Int. Appl., 66pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2009016142	A1	20090205	WO 2008-EP59848	20080728
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20090036388	A1	20090205	US 2008-180675	20080728
PRIORITY APPLN. INFO.:			US 2007-952649P	P 20070730
OTHER SOURCE(S):	CASREACT 150:168690; MARPAT 150:168690			


IT **1104201-23-1P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 9-deoxy-9A-methyl-9A-aza-9A-homo-erythromycin A derivs. and their use for treatment of malaria)

RN 1104201-23-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
4-(acetyloxy)-11-[[2-O-[3-[(7-chloro-4-quinolinyl)amino]propyl]-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-
3,10,13-trihydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



-----OAc

IT 1104201-21-9P 1104201-24-2P 1104201-27-5P
 1104201-29-7P 1104201-34-4P 1104201-38-8P
 1104201-41-3P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9-deoxy-9A-methyl-9A-aza-9A-homo-erythromycin A derivs. and their use for treatment of malaria)

RN 1104201-21-9 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-[3-[[4-[(7-chloro-4-quinolinyl)amino]-1-oxobutyl]amino]propyl]-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1104201-24-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-[3-[(7-chloro-4-quinolinyl)amino]propyl]-3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-
 tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.




-----OH

RN 1104201-27-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-[3-[[2-[(7-chloro-4-quinolinyl)amino]acetyl]amino]propyl]-3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-
 3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 1104201-29-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-2-O-[3-[[2-(4-
 quinolinylamino)acetyl]amino]propyl]-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 1104201-34-4 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethylamino)-2-O-[3-[(4-quinolinylmethyl)amino]propyl]-
β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 1104201-38-8 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-2-O-[3-[(3-quinolinylmethyl)amino]propyl]-
 β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 1104201-41-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-2-O-[3-[methyl(3-quinolinylmethyl)amino]propyl]-
 β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
 (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:24535 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 150:77903
 TITLE: Preparation of
 descladinose-clarithromycin-azithromycin non-peptide
 macrocyclic histone deacetylase (HDAC) inhibitors
 INVENTOR(S): Oyelere, Adegboyega
 PATENT ASSIGNEE(S): Georgia Tech Research Corporation, USA
 SOURCE: PCT Int. Appl., 69pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009006403	A2	20090108	WO 2008-US68787	20080630
WO 2009006403	A3	20100107		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-947036P P 20070629

OTHER SOURCE(S): CASREACT 150:77903; MARPAT 150:77903

IT 1093856-85-9P 1093856-87-1P 1093856-89-3P
1093857-08-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of descladinose-clarithromycin-azithromycin non-peptide
 macrocyclic histone deacetylase (HDAC) inhibitors)


RN 1093856-85-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
 trideoxy-3-[[[4-[1-[6-(hydroxyamino)-6-oxohexyl]-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 1093856-87-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
 trideoxy-3-[[[4-[1-[7-(hydroxyamino)-7-oxoheptyl]-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 1093856-89-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
 trideoxy-3-[[[4-[1-[8-(hydroxyamino)-8-oxooctyl]-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 1093857-08-9 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-[[[4-[[8-(hydroxyamino)-1,8-
dioxooctyl]amino]phenyl]methyl]methylamino]-β-D-xylo-
hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
NAME)

Absolute stereochemistry.

IT **1093857-07-8P**



RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of descladinose-clarithromycin-azithromycin non-peptide macrocyclic histone deacetylase (HDAC) inhibitors)

RN 1093857-07-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[[4-[(8-methoxy-1,8-dioxooctyl)amino]phenyl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **1093856-82-6P** **1093856-93-9P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of descladinose-clarithromycin-azithromycin non-peptide macrocyclic histone deacetylase (HDAC) inhibitors)

RN 1093856-82-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[[4-ethynylphenyl)methyl]methylamino]-β-D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)



Absolute stereochemistry.





RN 1093856-93-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[[4-[1-(6-methoxy-6-oxohexyl)-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

L21 ANSWER 7 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1526223 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 150:113716
 TITLE: Non-Peptide Macrocyclic Histone Deacetylase Inhibitors
 AUTHOR(S): Oyelere, Adegboyega K.; Chen, Po C.; Guerrant,
 William; Mwakwari, Sandra C.; Hood, Rebecca; Zhang,
 Yunzhe; Fan, Yuhong

CORPORATE SOURCE: School of Chemistry and Biochemistry, School of
Biology and Parker H. Petit Institute for
Bioengineering and Bioscience, Georgia Institute of
Technology, Atlanta, GA, 30332-0400, USA

SOURCE: Journal of Medicinal Chemistry (2009), 52(2), 456-468
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:113716

IT 1093856-85-9P 1093856-87-1P 1093856-89-3P
1093857-08-9P


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(non-peptide macrocyclic histone deacetylase inhibitors preparation)

RN 1093856-85-9 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
trideoxy-3-[[[4-[1-[6-(hydroxyamino)-6-oxohexyl]-1H-1,2,3-triazol-4-
yl]phenyl]methyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 1093856-87-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
 trideoxy-3-[[[4-[1-[7-(hydroxyamino)-7-oxoheptyl]-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B





RN 1093856-89-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
 trideoxy-3-[[[4-[1-[8-(hydroxyamino)-8-oxooctyl]-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1093857-08-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[[4-[[8-(hydroxyamino)-1,8-
 dioxooctyl]amino]phenyl]methyl]methylamino]-β-D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)


Absolute stereochemistry.



IT **1093856-82-6P** **1093856-93-9P** **1093857-07-8P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (non-peptide macrocyclic histone deacetylase inhibitors preparation)
 RN 1093856-82-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[4-ethynylphenyl)methyl]methylamino]-β-D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)



Absolute stereochemistry.







RN 1093856-93-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[[4-[1-(6-methoxy-6-oxohexyl)-1H-1,2,3-triazol-4-
 yl]phenyl]methyl]methylamino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1093857-07-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[[4-[(8-methoxy-1,8-
 dioxooctyl)amino]phenyl]methyl]methylamino]- β -D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 8 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:398289 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 148:456456

TITLE: Synthesis of azithromycin derivative used as antibacterial agents

INVENTOR(S): Shen, Shunyi; Huang, Xinyan; Ge, Han

PATENT ASSIGNEE(S): Shanghai Institute of Pharmaceutical Industry, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 28pp. CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101148461	A	20080326	CN 2006-10116212	20060919
PRIORITY APPLN. INFO.:			CN 2006-10116212	20060919
OTHER SOURCE(S): MARPAT 148:456456				

IT **152235-41-1P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of azithromycin derivative used as antibacterial agents)

RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1018474-15-1P 1018474-16-2P 1018474-18-4P
1018474-19-5P 1018474-20-8P 1018474-21-9P
1018474-22-0P 1018474-23-1P 1018474-24-2P
1018474-25-3P 1018474-26-4P 1018474-27-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(synthesis of azithromycin derivative used as antibacterial agents)

RN 1018474-15-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-10-hydroxy-3,4-dimethoxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-
phenyl-2-propen-1-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-
xylo-hexopyranosyl]oxy]-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 1018474-16-2 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-10-hydroxy-3,4-dimethoxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-
(1-naphthalenyl)-2-propen-1-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)-
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 1018474-18-4 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-10-hydroxy-3,4-dimethoxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-(3-quinolinyl)-2-propen-1-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)-
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 1018474-19-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[(2E)-3-[1,1'-biphenyl]-4-yl-2-propen-1-yl]oxy]-2-ethyl-10-hydroxy-3,4-
 dimethoxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 1018474-20-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-10-hydroxy-3,4-dimethoxy-3,5,6,8,10,12,14-heptamethyl-13-(2-propen-
 1-yloxy)-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 1018474-21-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-phenyl-
 2-propen-1-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 1018474-22-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-(1-
 naphthalenyl)-2-propen-1-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 1018474-23-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-(3-
 quinolinyl)-2-propen-1-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 1018474-24-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[(2E)-3-[1,1'-biphenyl]-4-yl-2-propen-1-yl]oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 1018474-25-3 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-(2-propen-1-
yloxy)-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
NAME)

Absolute stereochemistry.




RN 1018474-26-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,10-dihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2E)-3-phenyl-2-propen-1-yl]oxy]-4-(2-propen-1-yloxy)-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 1018474-27-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[(2E)-3-[1,1'-biphenyl]-4-yl-2-propen-1-yl]oxy]-2-ethyl-3,10-dihydroxy-3,5,6,8,10,12,14-heptamethyl-4-(2-propen-1-yloxy)-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.





IT 1018474-29-7P 1018474-30-0P 1018474-32-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of azithromycin derivative used as antibacterial agents)

RN 1018474-29-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-10,13-dihydroxy-3,4-dimethoxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1018474-30-0 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-10-hydroxy-3,4-dimethoxy-3,5,6,8,10,12,14-
heptamethyl-13-(2-propen-1-yloxy)-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 1018474-32-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 13-(2-propen-1-yloxy)-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)

Absolute stereochemistry.



L21 ANSWER 9 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1300923 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 147:542068
 TITLE: Preparation of erythromycin derivatives as MMP
 inhibitors
 INVENTOR(S): Kashimura, Masato; Kawamura, Madoka; Asaka, Toshifumi;
 Takayama, Kiyoshi; Ogita, Haruhisa
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 234 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007129646	A1	20071115	WO 2007-JP59327	20070501
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 2077271	A1	20090708	EP 2007-742762	20070501
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,			

AL, BA, HR, MK, RS				
US 20090076253	A1	20090319	US 2008-299229	20081031
CN 101454334	A	20090610	CN 2007-80020064	20081201
PRIORITY APPLN. INFO.:			JP 2006-127277	A 20060501
			JP 2007-881	A 20070106
			WO 2007-JP59327	W 20070501

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 147:542068


IT **957063-28-4P** **957063-29-5P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of erythromycin derivs. as MMP inhibitors for treatment of oncogenic angiogenesis, chronic rheumatoid arthritis)

RN 957063-28-4 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(3-methoxy-3-oxo-1-propen-1-yl)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 957063-29-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(3-methoxy-3-oxopropyl)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **957063-18-2P** **957063-21-7P** **957063-56-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of erythromycin derivs. as MMP inhibitors for treatment of oncogenic angiogenesis, chronic rheumatoid arthritis)

RN 957063-18-2 CAPLUS

CN 3-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(3-oxo-1-buten-1-yl)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 957063-21-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-[methyl(phenylmethyl)amino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 957063-56-8 CAPLUS

CN Benzeneacetic acid, 4-methoxy-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(3-methoxy-3-oxopropyl)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **313062-45-2**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of erythromycin derivs. as MMP inhibitors for treatment of oncogenic angiogenesis, chronic rheumatoid arthritis)

RN 313062-45-2 CAPLUS

CN 3-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **117693-41-1P** **152235-41-1P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of erythromycin derivs. as MMP inhibitors for treatment of oncogenic angiogenesis, chronic rheumatoid arthritis)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 10 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:939993 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 147:292225
TITLE: Use of cell-specific macrolide-antiinflammatory
molecule conjugates for treatment of inflammatory
diseases of the gastrointestinal tract
INVENTOR(S): Mercep, Mladen; Mesic, Milan; Tomaskovic, Linda;
Markovic, Stribor
PATENT ASSIGNEE(S): Glaxosmithkline Istrazivacki Centar Zagreb D.O.O.,
Croatia
SOURCE: PCT Int. Appl., 90pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007093840	A2	20070823	WO 2006-IB1488	20060215
WO 2007093840	A3	20080214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: WO 2006-IB1488 20060215

OTHER SOURCE(S): MARPAT 147:292225


IT 117693-41-1D, conjugates 905905-50-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(cell-specific macrolide-antiinflammatory mol. conjugate for treatment
of inflammatory disease of gastrointestinal tract)

RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 905905-50-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[methyl[3-[[[2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-3-
 pyridinyl]carbonyl]amino]propyl]amino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L21 ANSWER 11 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:220086 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 146:274569
 TITLE: Preparation of macrolide clarithromycin triazole
 glycosides as antiinfective, antiproliferative,
 antiinflammatory, and prokinetic agents
 INVENTOR(S): Bhattacharjee, Ashoke; Chen, Yi; Du, Yanming; Farmer,
 Jay J.; Goldberg, Joel A.; Kanyo, Zoltan F.; Lou,
 Rongliang; Sherer, Edward C.; Tang, Yuanqing; Wu,
 Yusheng
 PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 362pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007025098	A2	20070301	WO 2006-US33170	20060824
WO 2007025098	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1928893	A2	20080611	EP 2006-824847	20060824
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2009506066	T	20090212	JP 2008-528168	20060824
PRIORITY APPLN. INFO.: US 2005-711443P P 20050824				
US 2006-762907P P 20060126				
WO 2006-US33170 W 20060824				

OTHER SOURCE(S): CASREACT 146:274569; MARPAT 146:274569

IT **927666-56-6P** **927666-57-7P** **927666-58-8P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrolide clarithromycin triazole glycosides as antiinfective, antiproliferative, antiinflammatory, and prokinetic agents)

RN 927666-56-6 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-[[2-[1-[(1S)-1-(fluoromethyl)-2-(4-
nitrophenyl)ethyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-xylo-
hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 927666-57-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-[[2-[1-[(1S)-1-(fluoromethyl)-2-[4-(3-
pyridinyl)phenyl]ethyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]- β -D-


xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 927666-58-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-[[2-[1-[(1S)-1-(fluoromethyl)-2-[4-(methylsulfonyl)phenyl]ethyl]-1H-
 1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-13-
 [[2,4,6-trideoxy-4-(formylamino)-3-C-methyl-3-O-methyl-α-L-ribo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 12 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:117952 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 146:206584
TITLE: Preparation of pyrrolizine and indolizine macrolide
conjugates as inhibitors of 5-lipoxygenase and
cyclooxygenase
INVENTOR(S): Laufer, Stefan; Albrecht, Wolfgang; Burnet, Michael;
Gutke, Hans-Juergen
PATENT ASSIGNEE(S): Merckle GmbH, Germany
SOURCE: PCT Int. Appl., 50pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007012464	A1	20070201	WO 2006-EP7339	20060725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006274197	A1	20070201	AU 2006-274197	20060725
CA 2615581	A1	20070201	CA 2006-2615581	20060725
EP 1907392	A1	20080409	EP 2006-776400	20060725
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2009502838	T	20090129	JP 2008-523223	20060725
CN 101228171	A	20080723	CN 2006-80027173	20080124
IN 2008CN00429	A	20080919	IN 2008-CN429	20080125
US 20090221697	A1	20090903	US 2008-996801	20080627
PRIORITY APPLN. INFO.:			US 2005-702775P	P 20050726
			WO 2006-EP7339	W 20060725

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:206584; MARPAT 146:206584

IT **922724-94-5P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolizine and indolizine macrolide conjugates as inhibitors of 5-lipoxygenase and cyclooxygenase)

RN 922724-94-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-[2-[6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl-1H-pyrrolizin-5-yl]acetyl]-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **117693-41-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolizine and indolizine macrolide conjugates as inhibitors of 5-lipoxygenase and cyclooxygenase)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 13 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:1206730 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 145:505699
 TITLE: Preparation of 4"-amino linked erythromycin macrolides useful for the treatment of microbial infection
 INVENTOR(S): Alihodzic, Suleijam; Lazarevski, Gorjana
 PATENT ASSIGNEE(S): Glaxosmithkline Istrazivacki Centar Zagreb D.O.O., Croatia
 SOURCE: PCT Int. Appl., 80pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006120545	A1	20061116	WO 2006-IB1213	20060509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1879904	A1	20080123	EP 2006-744678	20060509
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2008540504	T	20081120	JP 2008-510662	20060509
US 20080312167	A1	20081218	US 2008-913853	20080711
PRIORITY APPLN. INFO.:			US 2005-679778P	P 20050510
			WO 2006-IB1213	W 20060509

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S) :

MARPAT 145:505699

IT 914987-08-9P 914987-09-0P 914987-10-3P
914987-11-4P 914987-12-5P 914987-14-7P
914987-16-9P 914987-17-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 4"-amino linked erythromycin macrolides useful for the treatment of microbial infection)


RN 914987-08-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[[[4-[[[3-[2-[2-[(3-carboxy-7-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)amino]ethoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 914987-09-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[2-[(3-carboxy-7-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinoliny]amino]ethoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.






RN 914987-10-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[3-(3-carboxy-1-ethyl-1,4-dihydro-4-oxo-6-
 quinolinyl)propoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-
 O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
 INDEX NAME)


Absolute stereochemistry.






RN 914987-11-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[3-[3-carboxy-1-(dimethylamino)-1,4-dihydro-4-oxo-6-
 quinolinyl]propoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-
 O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
 INDEX NAME)


Absolute stereochemistry.






RN	914987-12-5	CAPLUS
CN	1-Oxa-6-azacyclopentadecan-15-one, 13-[[4-[[3-[2-[3-[3-carboxy-1,4-dihydro-1-(2-methoxyethyl)-4-oxo-6-quinolinyl]propoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)	


Absolute stereochemistry.






RN	914987-14-7	CAPLUS
CN	1-Oxa-6-azacyclopentadecan-15-one, 13-[[4-[[3-[2-[3-(3-carboxy-1-ethyl-1,4-dihydro-4-oxo-6-quinolinyl)propoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)	


Absolute stereochemistry.






RN 914987-16-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[2-[(3-carboxy-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)amino]ethoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.






RN 914987-17-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[2-[(3-carboxy-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)amino]ethoxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **92395-24-9**

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of 4"-amino linked erythromycin macrolides useful for the treatment of microbial infection)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,

13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT **97240-71-6P 97240-76-1P 97276-94-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4"-amino linked erythromycin macrolides useful for the treatment of microbial infection)


RN 97240-71-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 97240-76-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 (hydroxyimino)-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 97276-94-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,

13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 14 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:823419 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 145:241730
 TITLE: Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
 INVENTOR(S): Mercep, Mladen; Mesic, Milan; Tomaskovic, Linda; Markovic, Stribor
 PATENT ASSIGNEE(S): Pliva-Istrazivacki Institut d.o.o., Croatia
 SOURCE: U.S. Pat. Appl. Publ., 53pp., Cont.-in-part of U.S. Ser. No. 201,685.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060183696	A1	20060817	US 2006-355808	20060215
US 20060035845	A1	20060216	US 2005-201685	20050810
AU 2005273592	A1	20060223	AU 2005-273592	20050810
CA 2576291	A1	20060223	CA 2005-2576291	20050810
EP 1778292	A2	20070502	EP 2005-786822	20050810
R: AT, BE, BG, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101043907	A	20070926	CN 2005-80034852	20050810
JP 2008509899	T	20080403	JP 2007-525378	20050810
BR 2005014254	A	20080603	BR 2005-14254	20050810
ZA 2007000668	A	20080827	ZA 2007-668	20070124

MX 2007001669	A	20070410	MX 2007-1669	20070209
IN 2007DN01351	A	20070803	IN 2007-DN1351	20070220
NO 2007001244	A	20070417	NO 2007-1244	20070307
KR 2007046917	A	20070503	KR 2007-705633	20070309
PRIORITY APPLN. INFO.:			US 2004-601087P	P 20040812
			US 2004-603315P	P 20040819
			US 2005-201685	A2 20050810
			WO 2005-IB2406	W 20050810

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:241730

IT **117693-41-1D**, conjugates with anti-inflammatory agents
905905-50-2


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(use of immune cell specific conjugates of macrolides linked to an
 anti-inflammatory subunit with low bioavailability for treatment of
 inflammatory diseases of gastrointestinal tract)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 905905-50-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[methyl[3-[[[2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-3-
 pyridinyl]carbonyl]amino]propyl]amino]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 15 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:736464 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 145:189119
 TITLE: Preparation of decladinosyl-macrolides with
 anti-inflammatory activity
 INVENTOR(S): Culic, Ognjen; Bosnar, Martina; Alihodzic, Sulejman;
 Lazarevski, Gorjana; Istuk Marusic, Zorica; Hutinec,
 Antun; Vela, Vanja; Kragol, Goran
 PATENT ASSIGNEE(S): GlaxoSmithKline Istrazivacki Centar Zagreb D.O.O.,
 Croatia
 SOURCE: PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006077501	A2	20060727	WO 2006-IB1097	20060113
WO 2006077501	A3	20061109		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,

SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1841776 A2 20071010 EP 2006-727561 20060113
 EP 1841776 B1 20081231
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU
 JP 2008526946 T 20080724 JP 2007-550875 20060113
 AT 419261 T 20090115 AT 2006-727561 20060113
 ES 2317527 T3 20090416 ES 2006-727561 20060113
 US 20080234211 A1 20080925 US 2007-813876 20071008
 PRIORITY APPLN. INFO.: US 2005-643840P P 20050113
 WO 2006-IB1097 W 20060113

OTHER SOURCE(S): CASREACT 145:189119; MARPAT 145:189119

IT **902122-66-1P** **902122-67-2P**


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of decladinosyl-macrolides with antiinflammatory activity)

RN 902122-66-1 CAPLUS

CN β -Alanine, N,N-diethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-
 3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-
 azacyclopentadec-13-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 902122-67-2 CAPLUS

CN Glycine, N,N-diethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-
 13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **117693-41-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of decladinosyl-macrolides with antiinflammatory activity)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **902122-65-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of decladinosyl-macrolides with antiinflammatory activity)

RN 902122-65-0 CAPLUS

CN 2-Propenoic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-
trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-
13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 16 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:679098 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 145:124814
 TITLE: Preparation of 9A,11-2C-bicyclic 9a-azalide erythromycin derivatives as prodrugs and antibacterial agents
 INVENTOR(S): Or, Yat Sun; Phan, Ly Tam; Wang, Guoqiang; Wang, Yanchun; Peng, Yulin
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 27 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060154881	A1	20060713	US 2006-324502	20060103
US 7271155	B2	20070918		
WO 2006078450	A1	20060727	WO 2006-US202	20060104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-642235P P 20050107
 US 2006-324502 A 20060103

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:124814; MARPAT 145:124814


IT **620169-47-3**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 9A,11-2C-bicyclic 9a-azalide erythromycin derivs. as

prodrugs and antibacterial agents)
 RN 620169-47-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-
 3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 17 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:412088 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 144:450549
 TITLE: Conjugates with anti-inflammatory activity
 INVENTOR(S): Mercep, Mladen; Mesic, Milan; Tomaskovic, Linda;
 Markovic, Stribor; Poljak, Visnja; Sijan, Gordana;
 Selmani, Selvira
 PATENT ASSIGNEE(S): Pliva-Istrazivacki Institut D.O.O., Croatia
 SOURCE: PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006046123	A2	20060504	WO 2005-IB3213	20051027
WO 2006046123	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2005298312	A1	20060504	AU 2005-298312	20051027
CA 2585711	A1	20060504	CA 2005-2585711	20051027
EP 1805202	A2	20070711	EP 2005-824103	20051027
EP 1805202	B1	20091230		

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR

CN 101090908	A	20071219	CN 2005-80045145	20051027
BR 2005017024	A	20080325	BR 2005-17024	20051027
JP 2008517993	T	20080529	JP 2007-538531	20051027
AT 453658	T	20100115	AT 2005-824103	20051027
ZA 2007002579	A	20080827	ZA 2007-2579	20070328
IN 2007DN02459	A	20070504	IN 2007-DN2459	20070402
MX 2007005073	A	20070625	MX 2007-5073	20070426
KR 2007083811	A	20070824	KR 2007-709486	20070426
US 20090048221	A1	20090219	US 2007-718505	20070502
NO 2007002684	A	20070711	NO 2007-2684	20070525

PRIORITY APPLN. INFO.:

US 2004-623154P	P	20041027
WO 2005-IB3213	W	20051027

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:450549; MARPAT 144:450549

IT **117693-42-2P** **885313-46-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of steroid and NSAID conjugates with macrolides for therapeutic
 use in the treatment of inflammatory and immune disorders)

RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 885313-46-2 CAPLUS

CN Carbamic acid, (4-aminobutyl)-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)-2-
 ethyl-3,10,11,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-
 azacyclopentadec-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 18 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:601329 CAPLUS <<LOGINID::20100317>>
Correction of: 2004:785009
DOCUMENT NUMBER: 143:96897
Correction of: 141:295411
TITLE: Product subclass 2: aluminum hydrides
AUTHOR(S): Saito, S.
CORPORATE SOURCE: Graduate School of Engineering, Nagoya University,
Chikusa, Nagoya, 464-8603, Japan
SOURCE: Science of Synthesis (2004), 7, 15-94
CODEN: SSCYJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT **171661-67-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aluminum hydrides and application to organic synthesis)
RN 171661-67-9 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,6S)-
tetrahydro-4,6-dimethyl-5-oxo-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **171661-68-0P** **171865-16-0P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of aluminum hydrides and application to organic synthesis)

RN 171661-68-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,5R,6S)-
tetrahydro-5-hydroxy-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 171865-16-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,5S,6S)-
tetrahydro-5-hydroxy-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 19 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:1016062 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 142:6762
TITLE: Preparation of azithromycin macrolides substituted at
the 4"-position as antibacterial agents
INVENTOR(S): Alihodzic, Sulejman; Berdik, Andrea; Jarvest, Richard
Lewis; Lazarevski, Gorjana
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Pliva-Istrazivacki Institut
D.O.O.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004101590	A1	20041125	WO 2004-EP5086	20040511
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2525459	A1	20041125	CA 2004-2525459	20040511
EP 1633765	A1	20060315	EP 2004-732099	20040511
EP 1633765	B1	20071114		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1820016	A	20060816	CN 2004-80019644	20040511

JP 2006528668	T	20061221	JP 2006-529797	20040511
AT 378347	T	20071115	AT 2004-732099	20040511
ES 2295865	T3	20080416	ES 2004-732099	20040511
IN 2005KN02188	A	20060929	IN 2005-KN2188	20051107
US 20080221158	A1	20080911	US 2006-556709	20060619
PRIORITY APPLN. INFO.:			GB 2003-10992	A 20030513
			WO 2004-EP5086	W 20040511

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:6762

IT **92395-24-9**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of azithromycin macrolides substituted at 4"-position as antibacterial agents)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **97240-71-6P** **97240-76-1P** **97276-94-3P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azithromycin macrolides substituted at 4"-position as antibacterial agents)

RN 97240-71-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 97240-76-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-(hydroxyimino)-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranosyl]oxy]-
, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 97276-94-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-
, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 797059-36-0P 797059-37-1P 797059-38-2P
797059-39-3P 797059-40-6P 797059-43-9P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of azithromycin macrolides substituted at 4"-position as
antibacterial agents)


RN 797059-36-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[[[4-[[[3-[2-[(3-carboxy-7-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-6-
quinolinyl)amino]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-
methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 797059-37-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[(3-carboxy-7-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)amino]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.






RN	797059-38-2	CAPLUS
CN	1-Oxa-6-azacyclopentadecan-15-one, 13-[[4-[[3-[2-[(3-carboxy-7-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)oxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-	(CA INDEX NAME)

Absolute stereochemistry.







RN 797059-39-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[(3-carboxy-7-chloro-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)oxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 797059-40-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[3-[2-[(3-carboxy-1-cyclopropyl-1,4-dihydro-4-oxo-6-quinolinyl)oxy]ethoxy]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 797059-43-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[[(4S)-4-[[3-[[2-[[7-chloro-1-cyclopropyl-1,4-dihydro-3-(methoxycarbonyl)-4-oxo-6-quinolinyl]amino]ethyl]methylamino]-1-oxopropyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 20 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:580666 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 141:123861
TITLE: Preparation of 9a-azalides with antibacterial activity
INVENTOR(S): Or, Yat Sun; Keyes, Robert F.; Ma, Zhenkun
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 26 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6764996	B1	20040720	US 2000-624849	20000725
PRIORITY APPLN. INFO.:			US 1999-150490P	P 19990824

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 141:123861; MARPAT 141:123861


IT **326813-41-6P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 9a-azalides and their antibacterial activity)

RN 326813-41-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,13-trihydroxy-3,5,6,8,10,12,14-heptamethyl-10-(2-propen-1-
yloxy)-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
NAME)

Absolute stereochemistry.




IT **326813-43-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 9a-azalides and their antibacterial activity)

RN 326813-43-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-2-ethyl-3,4,13-trihydroxy-3,5,6,8,10,12,14-heptamethyl-10-(2-propen-1-yloxy)-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 21 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:390261 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 140:386029

TITLE: 9a-Azalides with antiinflammatory activity, and preparation thereof

INVENTOR(S): Napoletano, Mauro; Mereu, Andrea; Moriggi, Ermanno; Ornaghi, Fernando; Morazzoni, Gabriele; Pellacini, Franco

PATENT ASSIGNEE(S): Zambon Group S.P.A., Italy


SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039821	A1	20040513	WO 2003-EP12071	20031028
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2502347	A1	20040513	CA 2003-2502347	20031028
AU 2003276214	A1	20040525	AU 2003-276214	20031028
AU 2003276214	B2	20090528		
EP 1556397	A1	20050727	EP 2003-809747	20031028
EP 1556397	B1	20060308		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1708507	A	20051214	CN 2003-80102350	20031028
CN 100486985	C	20090513		
AT 319729	T	20060315	AT 2003-809747	20031028
JP 2006513157	T	20060420	JP 2004-547618	20031028
RU 2320668	C2	20080327	RU 2005-116248	20031028
US 20060166904	A1	20060727	US 2005-531462	20050415
US 7419961	B2	20080902		
PRIORITY APPLN. INFO.:			IT 2002-MI2292	A 20021029
			WO 2003-EP12071	W 20031028
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 140:386029				
IT	<u>620169-54-2P</u>	<u>688002-49-5P</u>	<u>688002-50-8P</u>	
	<u>688002-52-0P</u>	<u>688002-54-2P</u>		
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(9a-azalides with antiinflammatory activity, and preparation thereof)				
RN	620169-54-2 CAPLUS			
CN	1-Oxa-6-azacyclopentadecan-15-one, 11-[[(2S,3R,6R)-3,6-dihydro-3-hydroxy-6-methyl-2H-pyran-2-yl]oxy]-2-ethyl- 3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)			


Absolute stereochemistry.



RN 688002-49-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethyloxidoamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688002-50-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethyloxidoamino)-β-D-xylo-hexopyranosyl]oxy]-,
6-oxide, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 688002-52-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-
[[(2S,3R,6R)-tetrahydro-3-hydroxy-6-methyl-2H-pyran-2-yl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 688002-54-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[3-(acetylmethylamino)-3,4,6-trideoxy- β -D-xylo-hexopyranosyl]oxy]-
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 22 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:292029 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 140:321158

TITLE: Methods of preparation of bifunctional heterocyclic
compounds for use as antiinfective, antiproliferative,
antiinflammatory and prokinetic agents

INVENTOR(S): Wang, Deping; Sutcliffe, Joyce A.; Oyelere, Adegboyega
K.; Mcconnell, Timothy S.; Ippolito, Joseph A.;
Abelson, John N.

PATENT ASSIGNEE(S): Rib-X Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 363 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004029066	A2	20040408	WO 2003-US30478	20030926
WO 2004029066	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278995	A1	20040419	AU 2003-278995	20030925
US 20050197334	A1	20050908	US 2003-671326	20030925
US 7091196	B2	20060815		
CA 2500158	A1	20040408	CA 2003-2500158	20030926
EP 1543017	A2	20050622	EP 2003-770506	20030926
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503848	T	20060202	JP 2004-540011	20030926
US 20060264385	A1	20061123	US 2006-359820	20060221
US 7335753	B2	20080226		
US 20080119419	A1	20080522	US 2007-4957	20071221
PRIORITY APPLN. INFO.:				
			US 2002-414207P	P 20020926
			US 2003-448216P	P 20030219
			US 2003-671326	A1 20030925
			WO 2003-US30478	W 20030926
			US 2006-359820	A3 20060221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:321158

IT 677726-26-0P 677726-81-7P 677726-82-8P
677726-87-3P 677726-88-4P



RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bifunctional heterocyclic compds. for use as antiinfective, antiproliferative, antiinflammatory and prokinetic agents)

RN 677726-26-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-trideoxy-3-[[2-[1-[[[5R]-3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 677726-81-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[[3,4,6-
trideoxy-3-[[2-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-
1H-1,2,3-triazol-4-yl]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.







RN 677726-82-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-[[4-[1-[[(5R)-3-(3-fluorophenyl)-2-oxo-5-oxazolidinyl]methyl]-
1H-1,2,3-triazol-4-yl]butyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-
, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 677726-87-3 CAPLUS



CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-

Absolute stereochemistry.

The chemical structure shows a complex molecule with multiple stereocenters and functional groups. It includes a sugar moiety (pyranose ring) linked to a complex chain containing several chiral centers, a carbonyl group, and a terminal ether group. Stereochemistry is indicated with wedges and dashes at various positions.

Chemical structure of a substituted 1,2,4-triazole derivative. The structure features a 1,2,4-triazole ring substituted with a methyl group at the 5-position. This triazole is connected via its 1-position to a 1,3-dioxolane ring. The 2-position of the dioxolane ring is substituted with a 4-fluorophenyl group. The 4-position of the dioxolane ring is labeled with 'R'.

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 23 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:41491 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 140:111632
TITLE: Preparation of steroid-containing macrolide
erythromycin analog glycosides for treatment of
inflammatory diseases
INVENTOR(S): Mercep, Mladen; Mesic, Milan; Tomaskovic, Linda;
Markovic, Stribor; Makaruha, Oresta; Poljak, Visnja
PATENT ASSIGNEE(S): Pliva D.D., Croatia
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2004005310	A2	20040115	WO 2003-HR37	20030708
WO 2004005310	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2489402	A1	20040115	CA 2003-2489402	20030708
US 20040014685	A1	20040122	US 2003-615716	20030708
US 7091187	B2	20060815		
AU 2003255851	A1	20040123	AU 2003-255851	20030708
AU 2003255851	B2	20090723		
EP 1521764	A2	20050413	EP 2003-762825	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012634	A	20050510	BR 2003-12634	20030708
CN 1692123	A	20051102	CN 2003-816093	20030708
JP 2005535654	T	20051124	JP 2004-519021	20030708
NZ 537717	A	20060428	NZ 2003-537717	20030708
RU 2330858	C2	20080810	RU 2005-103226	20030708
NO 2005000570	A	20050304	NO 2005-570	20050202
IN 2005DN00399	A	20070302	IN 2005-DN399	20050202
PRIORITY APPLN. INFO.:			US 2002-394670P	P 20020708
			WO 2003-HR37	W 20030708

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:111632

IT 92395-23-8P 92395-24-9P 262449-47-8P
642989-30-8P 642989-34-2P 642989-38-6P


RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of steroid-containing macrolide erythromycin analog glycosides for treatment of inflammatory diseases)

RN 92395-23-8 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 92395-24-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262449-47-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[[(3S,4S,6R,8R)-8-methoxy-4,8-dimethyl-1,5-dioxaspiro[2.5]oct-6-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 642989-30-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(ethylmethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-
 erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 642989-34-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-erythro-hexopyranos-4-
 ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-
 [[3,4,6-trideoxy-3-(ethylmethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 642989-38-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[(3S,4S,6R,8R)-8-methoxy-4,8-dimethyl-1,5-
 dioxaspiro[2.5]oct-6-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(ethylmethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 24 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:901493 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 140:241166
 TITLE: Electrochemical oxidation of azithromycin and its
 derivatives
 AUTHOR(S): Mandic, Zoran; Weitner, Zlatko; Ilijas, Marina
 CORPORATE SOURCE: PLIVA Research Division, Zagreb, HR-10000, Croatia

SOURCE: Journal of Pharmaceutical and Biomedical Analysis
(2003), 33(4), 647-654
CODEN: JPBADA; ISSN: 0731-7085
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English


IT **117693-42-2**

RL: ANT (Analyte); ANST (Analytical study)
(electrochem. oxidation of azithromycin and its derivs.)

RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 25 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:678606 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 139:197709

TITLE: macrolide erythromycin conjugates of biologically
active compounds, methods for their preparation and
use, formulation, and pharmaceutical applications
thereof

INVENTOR(S): Burnet, Michael; Guse, Jan-Hinrich; Gutke,
Hans-Jurgen; Beck, Albert; Tsotsou, Georgia;
Droste-Borel, Irina; Reichert, Jeannette; Luyten,
Kattie; Busch, Maximilian; Wolff, Michael; Khobzaoui,
Moussa; Margutti, Simona; Meindl, Thomas; Kim, Gene;
Barker, Laurence

PATENT ASSIGNEE(S): Sympore G.m.b.H., Germany

SOURCE: PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070174	A2	20030828	WO 2003-US4609	20030214

WO 2003070174 A3 20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2476423 A1 20030828 CA 2003-2476423 20030214
AU 2003219770 A1 20030909 AU 2003-219770 20030214
AU 2003219770 B2 20081009
EP 1483277 A2 20041208 EP 2003-716044 20030214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
NZ 535354 A 20080131 NZ 2003-535354 20030214
IN 2004CN01815 A 20060616 IN 2004-CN1815 20040813
US 20050171342 A1 20050804 US 2005-504787 20050324
PRIORITY APPLN. INFO.: US 2002-357434P P 20020215
WO 2003-US4609 W 20030214

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197709


IT 152235-41-1P 586411-26-9P 586411-28-1P
586411-32-7P 586411-59-8P 586411-65-6P
586411-72-5P 586411-90-7P 586412-18-2P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 586411-26-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-tetradeoxy-3-[[2-[[2-[(2,6-dichloro-3-


methylphenyl)amino]benzoyl]oxy]ethyl]methylamino]-2-(dimethylamino)- β -
D-arabino-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 586411-28-1 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
tetraeoxy-2-(dimethylamino)-3-[[2-[[2-[(2,3-
dimethylphenyl)amino]benzoyl]oxy]ethyl]methylamino]- β -D-arabino-
hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
NAME)


Absolute stereochemistry.



RN 586411-32-7 CAPLUS

CN Benzoic acid, 2-(acetyloxy)-, [[2-[[[(2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-2-oxoethyl]imino]di-2,1-ethanediyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.





RN 586411-59-8 CAPLUS

CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-[[2-[[[(2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-2-oxoethyl]amino]ethyl ester, (4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A







RN 586411-65-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
 tetra-deoxy-3-[[2-[[[(4E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-
 5-isobenzofuranyl)-4-methyl-1-oxo-4-hexen-1-yl]oxy]ethyl]methylamino]-2-
 (dimethylamino)- β -D-arabino-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.






RN 586411-72-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[[2-[[[(4E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-
 5-isobenzofuranyl)-4-methyl-1-oxo-4-
 hexenyl]oxy]ethyl]methylamino]acetyl]methylamino]-β-D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.








RN 586411-90-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
tetraoxy-2-(dimethylamino)-3-[[2-[4-[(2R,4R)-2-[2-[(1S,2S,6R,8S,8aR)-
1,2,6,7,8,8a-hexahydro-2,6-dimethyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-
naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl]-1,4-
dioxobutoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 586412-18-2 CAPLUS

CN Thymidine, 3'-azido-3'-deoxy-, 5',5'''-[[[2-
[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-
3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-2-
oxoethyl]imino]di-2,1-ethanediy] dipentanedioate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 117693-41-1P 117693-42-2P 586411-08-7P
 586412-21-7P 586412-23-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 586411-08-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
tetrahydroxy-2-(dimethylamino)-3-[(2-hydroxyethyl)methylamino]-β-D-
arabino-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 586412-21-7 CAPLUS

CN Acetic acid, 2-iodo-, (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 586412-23-9 CAPLUS

CN Glycine, N,N-bis(2-hydroxyethyl)-, (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **586411-61-2**


RL: RCT (Reactant); RACT (Reactant or reagent)

(macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 586411-61-2 CAPLUS

CN Glycine, N-(2-hydroxyethyl)-, (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 26 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:678605 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 139:197708
TITLE: macrolide erythromycin conjugates of biologically
active compounds, methods for their preparation and
use, formulation, and pharmaceutical applications
thereof
INVENTOR(S): Burnet, Michael; Guse, Jan-Hinrich; Kim, Gene; Beck,
Albert; Tsotsou, Georgia; Droste-Borel, Irina; Barker,
Laurence; Wolff, Michael; Gutke, Hans-Jurgen
PATENT ASSIGNEE(S): Sympore G.m.b.H., Germany
SOURCE: PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070173	A2	20030828	WO 2003-US4596	20030214
WO 2003070173	A3	20031204		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003215245	A1	20030909	AU 2003-215245	20030214
US 20040005641	A1	20040108	US 2003-367624	20030214
EP 1483579	A2	20041208	EP 2003-711061	20030214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 IN 2004CN01809 A 20060224 IN 2004-CN1809 20040813
 US 20060099660 A1 20060511 US 2005-504786 20050929
 US 20080145343 A1 20080619 US 2007-895295 20070823
 US 20090093014 A1 20090409 US 2008-157937 20080612
 PRIORITY APPLN. INFO.: US 2002-357589P P 20020215
 US 2003-367624 B1 20030214
 WO 2003-US4596 W 20030214
 US 2005-504786 B1 20050929

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:197708


IT 152235-41-1P 586411-26-9P 586411-28-1P
586411-32-7P 586411-59-8P 586411-65-6P
586411-72-5P 586411-90-7P 586412-18-2P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (macrolide erythromycin conjugates of biol. active compds. methods for
 their preparation and use formulation and pharmaceutical applications
 thereof)

RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
 heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 586411-26-9 CAPLUS



CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
 tetradeoxy-3-[[2-[[2-[(2,6-dichloro-3-
 methylphenyl)amino]benzoyl]oxy]ethyl]methylamino]-2-(dimethylamino)- β -
 D-arabino-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
 INDEX NAME)

Absolute stereochemistry.



RN 586411-28-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
 tetraoxy-2-(dimethylamino)-3-[[2-[[2-[(2,3-
 dimethylphenyl)amino]benzoyl]oxy]ethyl]methylamino]-β-D-arabino-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)


Absolute stereochemistry.



RN 586411-32-7 CAPLUS

CN Benzoic acid, 2-(acetyloxy)-, [[2-[[[(2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-2-oxoethyl]imino]di-2,1-ethanediyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.





RN 586411-59-8 CAPLUS

CN 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-[[2-[[[(2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-2-oxoethyl]amino]ethyl ester, (4E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A







RN 586411-65-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
tetradeoxy-3-[[2-[[[(4E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-
5-isobenzofuranyl)-4-methyl-1-oxo-4-hexen-1-yl]oxy]ethyl]methylamino]-2-
(dimethylamino)-β-D-arabino-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.






RN 586411-72-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-[[[2-[[[(4E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-
 5-isobenzofuranyl)-4-methyl-1-oxo-4-
 hexenyl]oxy]ethyl]methylamino]acetyl]methylamino]-β-D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.








RN 586411-90-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
 tetraoxy-2-(dimethylamino)-3-[[2-[4-[(2R,4R)-2-[2-[(1S,2S,6R,8S,8aR)-
 1,2,6,7,8,8a-hexahydro-2,6-dimethyl-8-[(2S)-2-methyl-1-oxobutoxy]-1-
 naphthalenyl]ethyl]tetrahydro-6-oxo-2H-pyran-4-yl]-1,4-
 dioxobutoxy]ethyl]methylamino]-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 586412-18-2 CAPLUS

CN Thymidine, 3'-azido-3'-deoxy-, 5',5'''-[[[2-
 [[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-
 3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-2-
 oxoethyl]imino]di-2,1-ethanediy] dipentanedioate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 117693-41-1P 117693-42-2P 586411-08-7P
 586412-21-7P 586412-23-9P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 586411-08-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[2,3,4,6-
tetrahydroxy-2-(dimethylamino)-3-[(2-hydroxyethyl)methylamino]-β-D-
arabino-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA
INDEX NAME)


Absolute stereochemistry.



RN 586412-21-7 CAPLUS

CN Acetic acid, 2-iodo-, (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 586412-23-9 CAPLUS

CN Glycine, N,N-bis(2-hydroxyethyl)-, (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **586411-61-2**


RL: RCT (Reactant); RACT (Reactant or reagent)

(macrolide erythromycin conjugates of biol. active compds. methods for their preparation and use formulation and pharmaceutical applications thereof)

RN 586411-61-2 CAPLUS

CN Glycine, N-(2-hydroxyethyl)-, (2R,3S,4R,5R,8R,10R,11R,12R,13S,14R)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 27 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:405926 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 139:230927
TITLE: Synthesis, stereochemical assignment and biological
activity of a novel series of C-4'' modified
aza-Macrolides
AUTHOR(S): Bronk, Brian S.; Letavic, Michael A.; Bertsche,
Camilla D.; George, David M.; Hayashi, Shigeru F.;
Kamicker, Barbara J.; Kolosko, Nicole L.; Norcia,
Laura J.; Rushing, Margaret A.; Santoro, Sheryl L.;
Yang, Bingwei V.
CORPORATE SOURCE: Groton Laboratories, Pfizer Global Research and
Development, Groton, CT, 06340, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003),
13(12), 1955-1958
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:230927
IT **592476-49-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis, stereochem. assignment and antibacterial structure-activity
of a novel series of C-4'' modified aza-macrolides)
RN 592476-49-8 CAPLUS
CN α -L-erythro-Hexopyranosid-4-ulose,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[[3,4,6-trideoxy-3-(dimethylamino)-
2-O-[(phenylmethoxy)carbonyl]- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-
azacyclopentadec-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 28 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:382282 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 139:117633
 TITLE: Synthesis and Antibacterial Activity of a Novel Series of Acylides: 3-O-(3-Pyridyl)acetylerythromycin A Derivatives
 AUTHOR(S): Tanikawa, Tetsuya; Asaka, Toshifumi; Kashimura, Masato; Suzuki, Keiko; Sugiyama, Hiroyuki; Sato, Masakazu; Kameo, Kazuya; Morimoto, Shigeo; Nishida, Atsushi
 CORPORATE SOURCE: Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., Kita Saitama, Saitama, 331-9530, Japan
 SOURCE: Journal of Medicinal Chemistry (2003), 46(13), 2706-2715
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:117633

IT **313062-45-2P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (synthesis and antibacterial activity of pyridylacetylerythromycin A acylide derivs.)
 RN 313062-45-2 CAPLUS
 CN 3-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **117693-41-1**


RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis and antibacterial activity of pyridylacetylerythromycin A acylide derivs.)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **152235-41-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(synthesis and antibacterial activity of pyridylacetylerythromycin A acylide derivs.)

RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-

heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 29 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:370759 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 139:357948
TITLE: Azithromycin metabolite identification in plasma, bile, and tissues of the ball python (*Python regius*)
AUTHOR(S): Hunter, R. P.; Koch, D. E.; Coke, R. L.; Goatley, M. A.; Isaza, R.
CORPORATE SOURCE: Departments of Anatomy and Physiology, Kansas State University, Manhattan, KS, USA
SOURCE: Journal of Veterinary Pharmacology and Therapeutics (2003), 26(2), 117-121
CODEN: JVPTD9; ISSN: 0140-7783
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 117693-41-1 620169-47-3 620169-49-5
620169-52-0 620169-54-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(azithromycin metabolite identification in plasma, bile, and tissues of the ball python (*Python regius*))
RN 117693-41-1 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 620169-47-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-
 3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 620169-49-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-
 3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (methylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 620169-52-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(methylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 620169-54-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-(2S,3R,6R)-3,6-dihydro-3-hydroxy-6-methyl-2H-pyran-2-yl]oxy]-2-ethyl-
3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 30 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:236036 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 139:194241
 TITLE: Azalide 3,6-Ketals: antibacterial activity and structure-Activity relationships of aryl and hetero aryl substituted analogues
 AUTHOR(S): Sakya, Subas M.; Bertinato, Peter; Pratt, Bryan; Suarez-Contreras, Melani; Lundy, Kristin M.; Minich, Martha L.; Cheng, Hengmiao; Ziegler, Carl B.; Kamicker, Barbara J.; Hayashi, Shigeru F.; Santoro, Sheryl L.; George, David M.; Bertsche, Camilla D.
 CORPORATE SOURCE: Veterinary Medicine Research and Development, Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(7), 1373-1375
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT **117693-41-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (antibacterial activity and structure-activity relationships of aryl and hetero aryl substituted analogs of azalide 3,6-ketals)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 31 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:135060 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 139:312557
TITLE: Analysis of unknown compounds in azithromycin bulk
samples with liquid chromatography coupled to ion trap
mass spectrometry
AUTHOR(S): Debremaeker, D.; Visky, D.; Chepkwony, H. K.; Van
Schepdael, A.; Roets, E.; Hoogmartens, J.
CORPORATE SOURCE: Faculteit Farmaceutische Wetenschappen, Laboratorium
voor Farmaceutische Chemie en Analyse van
Geneesmiddelen, Katholieke Universiteit Leuven,
Louvain, B-3000, Belg.
SOURCE: Rapid Communications in Mass Spectrometry (2003),
17(4), 342-350
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **117693-41-1**
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(anal. of unknown compds. in azithromycin bulk samples with liquid
chromatog. coupled to ion trap mass spectrometry)
RN 117693-41-1 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 32 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:585084 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 138:89600
 TITLE: Synthesis and SAR of azalide 3,6-ketal aromatic derivatives as potent gram-positive and gram-negative antibacterial agents
 AUTHOR(S): Cheng, Hengmiao; Dirlam, John P.; Ziegler, Carl B.; Lundy, Kristin M.; Hayashi, Shigeru F.; Kamicker, Barbara J.; Dutra, Jason K.; Daniel, Kirsten L.; Santoro, Sheryl L.; George, David M.; Bertsche, Camilla D.; Sakya, Subas M.; Suarez-Contreras, Melani
 CORPORATE SOURCE: Groton Laboratories, Pfizer Global Research and Development, Groton, CT, 06340, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(17), 2431-2434
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:89600

IT **117693-41-1**

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of azalide 3,6-ketal aromatic derivs. from a descladinose azalide

and their antibacterial activity for potential treatment of mastitis)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 33 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:539688 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 137:109163
TITLE: Preparation of conjugates of immune cell specific
macrolide compounds with anti-inflammatory compounds
for improved cellular targeting of anti-inflammatory
therapy
INVENTOR(S): Mercep, Mlanden; Mesic, Milan; Tomaskovic, Linda;
Komac, Marijana; Hrvacic, Boska; Markovic, Stribor
PATENT ASSIGNEE(S): Pliva D.D., Croatia
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055531	A1	20020718	WO 2002-HR1	20020103
W: BA, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IN, IS, JP, KP, LT, LV, MK, PL, SI, SK, UA, US, UZ, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
HR 2001000018	A1	20021231	HR 2001-18	20010109
CA 2434009	A1	20020718	CA 2002-2434009	20020103
CA 2434009	C	20090929		
EE 200300293	A	20031015	EE 2003-293	20020103
EP 1351973	A1	20031015	EP 2002-729470	20020103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, TR				
BR 2002006347	A	20040210	BR 2002-6347	20020103
CN 1491230	A	20040421	CN 2002-804715	20020103
CN 1269836	C	20060816		
JP 2004518670	T	20040624	JP 2002-556599	20020103
HU 2005000180	A2	20060928	HU 2005-180	20020103

HU 2005000180	A3	20091228		
IN 2003CN01176	A	20050422	IN 2003-CN1176	20030730
BG 108073	A	20050531	BG 2003-108073	20030807
US 20040198677	A1	20041007	US 2003-250934	20031229
US 7446097	B2	20081104		
HK 1065320	A1	20070404	HK 2004-108052	20041018
US 20090105163	A1	20090423	US 2008-211213	20080916
PRIORITY APPLN. INFO.:			HR 2001-18	A 20010109
			WO 2002-HR1	W 20020103
			US 2003-250934	A1 20031229

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:109163

IT 442638-77-9P 442639-00-1P 442639-05-6P
442639-09-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of conjugates of immune cell specific macrolide compds. with anti-inflammatory compds. for improved cellular targeting of anti-inflammatory therapy)

RN 442638-77-9 CAPLUS

CN Androsta-1,4-diene-17-carboxylic acid,
 9-fluoro-11,17-dihydroxy-16-methyl-3-oxo-,
 5-[[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl]oxy]-5-oxopentyl ester, (11 β ,16 α ,17 α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Me


RN 442639-00-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-2-O-[5-[[[(11 β ,16 α ,17 α)-9-
 fluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-
 yl]carbonyl]oxy]-1-oxopentyl]- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 442639-05-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-2-O-[5-
 [[[(6 α ,11 β ,16 α ,17 α)-6-fluoro-11,17-dihydroxy-16-
 methyl-3-oxoandrosta-1,4-dien-17-yl]carbonyl]oxy]-1-oxopentyl]- β -D-
 xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 442639-09-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-[5-[[[(6 α ,11 β ,16 α ,17 α)-9-chloro-6-fluoro-
 11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl]carbonyl]oxy]-1-
 oxopentyl]-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
 heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 117693-41-1 152235-41-1


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of conjugates of immune cell specific macrolide compds. with anti-inflammatory compds. for improved cellular targeting of anti-inflammatory therapy)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **442640-16-6P** **442640-27-9P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of conjugates of immune cell specific macrolide compds. with
anti-inflammatory compds. for improved cellular targeting of
anti-inflammatory therapy)

RN 442640-16-6 CAPLUS


CN Pentanoic acid, 5-bromo-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[[2-O-
acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-
ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-
azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 442640-27-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-(5-bromo-1-oxopentyl)-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptomethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 34 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:300707 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 137:284467
 TITLE: Optimization of triple quadrupole mass spectrometer for quantitation of trace degradants of pharmaceutical compounds
 AUTHOR(S): Jiao, Jim; Carella, Anthony J.; Steeno, Gregory S.; Darrington, Richard T.
 CORPORATE SOURCE: Pfizer Global Research and Development, Pharmaceutical Research and Development, Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: International Journal of Mass Spectrometry (2002), 216(2), 209-218
 CODEN: IMSPF8; ISSN: 1387-3806

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **117693-41-1**


RL: ANT (Analyte); ANST (Analytical study)

(quantitation of trace degradants of by triple quadrupole mass spectrometry and optimization of method)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 35 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:123024 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 136:184055

TITLE: Preparation of macrolide erythromycins and clarithromycins as antibiotics

INVENTOR(S): Chen, Yan; Su, Wei-Guo

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002012260	A1	20020214	WO 2001-IB1403	20010806
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,			

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 20020115621 A1 20020822 US 2001-920141 20010801
 CA 2419044 A1 20020214 CA 2001-2419044 20010806
 AU 2001072719 A 20020218 AU 2001-72719 20010806
 EP 1307468 A1 20030507 EP 2001-951875 20010806
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2001012863 A 20030701 BR 2001-12863 20010806
 JP 2004505987 T 20040226 JP 2002-518234 20010806
 MX 2003001148 A 20030609 MX 2003-1148 20030206
 US 20040009930 A1 20040115 US 2003-454354 20030603
 US 6849608 B2 20050201
 PRIORITY APPLN. INFO.: US 2000-223591P P 20000807
 US 2001-920141 B1 20010801
 WO 2001-IB1403 W 20010806

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:184055


IT **397867-28-6P**

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (preparation of macrolide erythromycins and clarithromycins as antibiotics)

RN 397867-28-6 CAPLUS

CN Benzeneacetic acid, α -(methoxymethoxy)-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA
 INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
 (10 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 36 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 2001:521899 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 135:92802
 TITLE: Preparation of erythromycin macrolides as bactericide and protozoacide agents
 INVENTOR(S): Wu, Yong-jin; Su, Wei-guo
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S., 46 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6262030	B1	20010717	US 1999-432500	19991102
PRIORITY APPLN. INFO.:			US 1998-106820P	P 19981103
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 135:92802		

IT **156885-01-7P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of erythromycin macrolides as bactericide and protozoacide agents)
 RN 156885-01-7 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,13-trihydroxy-10-methoxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 37 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:194797 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 134:247235
 TITLE: Macrolide based antimicrobial agents
 INVENTOR(S): Asaga, Toshifumi; Kashimura, Masato; Manaka, Akira; Tanigawa, Tetsuya; Sugimoto, Tomohiro
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
 CODEN: JKXXAF

DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001072699	A	20010321	JP 2000-197833	20000630
PRIORITY APPLN. INFO.:			JP 1999-187669	A 19990701
OTHER SOURCE(S):			MARPAT 134:247235	


IT **330783-47-6P** **330783-48-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (macrolide based antimicrobial agents)

RN 330783-47-6 CAPLUS

CN 2-Pyridineacetic acid, α -(hydroxyimino)-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA
 INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 330783-48-7 CAPLUS

CN 2-Pyridineacetic acid, α -(methoxyimino)-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




IT **152235-41-1**

RL: RCT (Reactant); RACT (Reactant or reagent)
(macrolide based antimicrobial agents)

RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **330783-49-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(macrolide based antimicrobial agents)

RN 330783-49-8 CAPLUS

CN 2-Pyridineacetic acid, α -(methoxyimino)-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[[2-O-acetyl-3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



L21 ANSWER 38 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:152702 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 134:178762
 TITLE: Preparation of macrolides 9a-azalide glycosides with
 antibacterial activity
 INVENTOR(S): Or, Yat Sun; Keyes, Robert F.; Ma, Zhenkun
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014397	A1	20010301	WO 2000-US20363	20000726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2380455	A1	20010301	CA 2000-2380455	20000726
CA 2380455	C	20090602		
BR 2000009101	A	20020205	BR 2000-9101	20000726
EP 1206476	A1	20020522	EP 2000-955256	20000726
EP 1206476	B1	20060104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003507487	T	20030225	JP 2001-518727	20000726
AT 315042	T	20060215	AT 2000-955256	20000726
PT 1206476	E	20060531	PT 2000-955256	20000726

ES 2256030	T3	20060716	ES 2000-955256	20000726
MX 2002001897	A	20021031	MX 2002-1897	20020222
HK 1047940	A1	20061103	HK 2002-107738	20021024
PRIORITY APPLN. INFO.:			US 1999-382166	A 19990824
			WO 2000-US20363	W 20000726

OTHER SOURCE(S): MARPAT 134:178762

IT **326813-41-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of macrolides aazalide glycosides with antibacterial activity)

RN 326813-41-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,13-trihydroxy-3,5,6,8,10,12,14-heptamethyl-10-(2-propen-1-yloxy)-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **326813-43-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of macrolides aazalide glycosides with antibacterial activity)

RN 326813-43-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-2-ethyl-3,4,13-trihydroxy-3,5,6,8,10,12,14-heptamethyl-10-(2-propen-1-yloxy)-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 39 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:887674 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 134:42385
 TITLE: Preparation of 15-membered ring macrolide compounds as antibacterial agents
 INVENTOR(S): Asaka, Toshifumi; Kashimura, Masato; Manaka, Akira
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000351792	A	20001219	JP 2000-94001	20000330
PRIORITY APPLN. INFO.:			JP 1999-97775	A 19990405
OTHER SOURCE(S):	MARPAT 134:42385			

IT **152235-41-1**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 15-membered ring macrolide compds. as antibacterial agents)
 RN 152235-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
 heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **313062-44-1P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 15-membered ring macrolide compds. as antibacterial agents)

RN 313062-44-1 CAPLUS

CN 2-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



IT **313062-43-0P**, 3-O-(2-Pyridyl)acetyl-5-O-desosaminyl-9-deoxo-9a-aza-9a-methyl-9a-homoerythronolide A **313062-45-2P**

313062-46-3P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 15-membered ring macrolide compds. as antibacterial agents)

RN 313062-43-0 CAPLUS

CN 2-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 313062-45-2 CAPLUS

CN 3-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 313062-46-3 CAPLUS

CN 4-Pyridineacetic acid, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 40 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2000:534855 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 133:120574
 TITLE: Preparation of azalide azithromycins as antibacterial and antitumor agents
 INVENTOR(S): O'Connell, Thomas Noel; Morse, Brook Knight; McArthur, Hamish Alastair Irvine; Dirlam, John Philip
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 36 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1024145	A2	20000802	EP 2000-300054	20000106
EP 1024145	A3	20010530		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2292359	A1	20000728	CA 1999-2292359	19991215
CA 2292359	C	20040928		
CA 2411293	A1	20000728	CA 1999-2411293	19991215
BR 2000000003	A	20010821	BR 2000-3	20000103
US 6270768	B1	20010807	US 2000-491254	20000126
JP 2000219697	A	20000808	JP 2000-20405	20000128
MX 2000001110	A	20010131	MX 2000-1110	20000131
PRIORITY APPLN. INFO.:			US 1999-117631P	P 19990128
			CA 1999-2292359	A3 19991215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 133:120574

IT 1100639-84-6 1100639-90-4 1100639-91-5


RL: PRPH (Prophetic)

(Preparation of azalide azithromycins as antibacterial and antitumor agents)

RN 1100639-84-6 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1100639-90-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1100639-91-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT **285567-69-3P**


RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azalide azithromycins as antibacterial and antitumor agents)

RN 285567-69-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-O-methyl- α -L-arabino-hexopyranosyl)oxy]-2-ethyl-
3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **117693-42-2**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of azalide azithromycins as antibacterial and antitumor agents)

RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 41 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2000:240737 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 132:251371
TITLE: Preparation of erythromycin derivatives as
antibacterial agents
INVENTOR(S): Bronk, Brian Scott; Cheng, Hengmiao; Dutra, Jason
Kenneth; Letavic, Michael Anthony; Rafka, Robert John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 52 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 992509	A2	20000412	EP 1999-307938	19991008
EP 992509	A3	20010307		
EP 992509	B1	20040922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6100240	A	20000808	US 1999-396876	19990916
CA 2286511	A1	20000409	CA 1999-2286511	19991007
CA 2286511	C	20030708		
JP 2000119294	A	20000425	JP 1999-286835	19991007
JP 3679656	B2	20050803		
MX 9909269	A	20001031	MX 1999-9269	19991008
AT 277062	T	20041015	AT 1999-307938	19991008
PT 992509	E	20041231	PT 1999-307938	19991008
ES 2226294	T3	20050316	ES 1999-307938	19991008
BR 9905089	A	20000808	BR 1999-5089	19991011
PRIORITY APPLN. INFO.:			US 1998-103838P	P 19981009
OTHER SOURCE(S):	MARPAT 132:251371			


IT **262449-50-3P** **262449-51-4P** **262449-52-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of erythromycin derivs. as antibacterial agents)

RN 262449-50-3 CAPLUS

CN 1,7-Dioxa-3-azaspiro[4.5]decane, 8-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl]oxy]-10-methoxy-6,10-dimethyl-3-(2-pyridinylcarbonyl)-, (5S,6S,8R,10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262449-51-4 CAPLUS

CN 1,7-Dioxa-3-azaspiro[4.5]decane, 8-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl]oxy]-10-methoxy-6,10-dimethyl-3-(3-pyridinylcarbonyl)-, (5S,6S,8R,10R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262449-52-5 CAPLUS

CN 1,7-Dioxa-3-azaspiro[4.5]decane, 8-[[(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadec-13-yl]oxy]-10-methoxy-6,10-dimethyl-3-(4-pyridinylcarbonyl)-, (5S,6S,8R,10R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **262449-47-8**

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of erythromycin derivs. as antibacterial agents)

RN 262449-47-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one, 2-ethyl-3,4,10-trihydroxy-13-[[(3S,4S,6R,8R)-8-methoxy-4,8-dimethyl-1,5-dioxaspiro[2.5]oct-6-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (5S,6S,8R,10R)- (9CI) (CA INDEX NAME)

(2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **262449-53-6P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of erythromycin derivs. as antibacterial agents)

RN 262449-53-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3, 4, 10-trihydroxy-13-[[(5S, 6S, 8R, 10R)-10-methoxy-6, 10-dimethyl-1, 7-dioxa-3-azaspiro[4.5]dec-8-yl]oxy]-3, 5, 6, 8, 10, 12, 14-heptamethyl-11-[[3, 4, 6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R, 3S, 4R, 5R, 8R, 10R, 11R, 12S, 13S, 14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L21 ANSWER 42 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:597476 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 131:199938
TITLE: Preparation of 3,6-ketal and enol ether macrolide
descladinose azithromycin antibiotics
INVENTOR(S): Lundy, Kristin M.; Cheng, Hengmiao; Sakya, Subas M.;
Bertinato, Peter; Minich, Martha L.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 941998	A2	19990915	EP 1999-301325	19990223
EP 941998	A3	19991006		
EP 941998	B1	20040901		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 275151	T	20040915	AT 1999-301325	19990223
PT 941998	E	20041231	PT 1999-301325	19990223
ES 2226282	T3	20050316	ES 1999-301325	19990223
US 6043226	A	20000328	US 1999-257709	19990225
CA 2263203	A1	19990903	CA 1999-2263203	19990301
CA 2263203	C	20020903		
NO 9901012	A	19990906	NO 1999-1012	19990302
NO 312366	B1	20020429		
HU 9900492	A2	19990928	HU 1999-492	19990302
HU 9900492	A3	20010828		
JP 11315093	A	19991116	JP 1999-53715	19990302
JP 3666788	B2	20050629		
NZ 334442	A	20000327	NZ 1999-334442	19990302
ZA 9901664	A	20001012	ZA 1999-1664	19990302
AU 9918562	A	19990916	AU 1999-18562	19990303
AU 741435	B2	20011129		
CN 1244532	A	20000216	CN 1999-105681	19990303
BR 9900856	A	20000425	BR 1999-856	19990303
PRIORITY APPLN. INFO.:			US 1998-76630P	P 19980303

OTHER SOURCE(S): MARPAT 131:199938

IT **241159-10-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3,6-ketal and enol ether macrolide descladinose azithromycin antibiotics)


RN 241159-10-4 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-(1-cyclohexen-1-yloxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **117693-41-1**, Descladinose azithromycin
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 3,6-ketal and enol ether macrolide descladinose azithromycin antibiotics)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)

L21 ANSWER 43 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:282227 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 130:282312
 TITLE: Preparation of erythromycin 3,6-hemiketals from the
 class of 9a-azalides as bactericides
 INVENTOR(S): Kobrehel, Gabrijela; Lazarevski, Gorjana; Vinkovic,
 Mladen
 PATENT ASSIGNEE(S): Pliva, Farmaceutska, Kemijska, Prehrambena I
 Kozmeticka Industrija, Dionicko, Croatia
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920639	A2	19990429	WO 1998-HR5	19981013
WO 9920639	A3	19990708		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
HR 9700551	A1	20001231	HR 1997-551 19971016
HR 9700551	B1	20051031	
HR 9800497	A1	20001231	HR 1998-497 19980910
HR 9800497	B1	20050831	
CA 2306963	A1	19990429	CA 1998-2306963 19981013
CA 2306963	C	20070501	
AU 9893622	A	19990510	AU 1998-93622 19981013
AU 755315	B2	20021212	
EP 1036083	A2	20000920	EP 1998-946627 19981013
EP 1036083	B1	20040526	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
HU 2000004085	A2	20010428	HU 2000-4085 19981013
HU 2000004085	A3	20030528	
EE 200000226	A	20010615	EE 2000-226 19981013
EE 4681	B1	20060815	
JP 2001520234	T	20011030	JP 2000-516980 19981013
NZ 503897	A	20021025	NZ 1998-503897 19981013
RU 2220148	C2	20031227	RU 2000-111996 19981013
AT 267835	T	20040615	AT 1998-946627 19981013
EP 1437359	A2	20040714	EP 2004-4844 19981013
EP 1437359	A3	20050330	
EP 1437359	B1	20061220	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, MK, AL			
PT 1036083	E	20041029	PT 1998-946627 19981013
ES 2222610	T3	20050201	ES 1998-946627 19981013
BR 9812808	A	20050412	BR 1998-12808 19981013
PL 191087	B1	20060331	PL 1998-340372 19981013
CN 1281615	C	20061025	CN 1998-811624 19981013
AT 348836	T	20070115	AT 2004-4844 19981013
IL 135648	A	20070308	IL 1998-135648 19981013
PT 1437359	E	20070430	PT 2004-4844 19981013
ES 2279242	T3	20070816	ES 2004-4844 19981013
SK 285914	B6	20071102	SK 2000-552 19981013
NO 2000001871	A	20000417	NO 2000-1871 20000411
MX 2000003644	A	20010306	MX 2000-3644 20000414
US 6369035	B1	20020409	US 2000-529642 20000417
BG 104445	A	20010228	BG 2000-104445 20000516
BG 64650	B1	20051031	
HK 1032785	A1	20070504	HK 2001-103498 20010522
PRIORITY APPLN. INFO.:			HR 1997-551 A 19971016
			HR 1998-497 A 19980910
			EP 1998-946627 A3 19981013
			WO 1998-HR5 W 19981013

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 130:282312

IT **117693-41-1P** **152235-41-1P** **222733-96-2P**
222733-97-3P **222734-02-3P** **222734-03-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of erythromycin 3,6-hemiketals from the class of 9a-azalides as
bactericides)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,

(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 152235-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 222733-96-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-4,10,13-trihydroxy-3-methoxy-3,5,6,8,10,12,14-heptamethyl-11-
[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 222733-97-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-4,10,13-trihydroxy-3-methoxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 222734-02-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,10,13-trihydroxy-4-methoxy-3,5,6,8,10,12,14-heptamethyl-11-
[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 222734-03-4 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,10,13-trihydroxy-4-methoxy-3,5,6,8,10,12,14-
 heptamethyl-, (2R,3R,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (10 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 44 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1999:194006 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 130:218265
 TITLE: 9a-Azalides as veterinary antimicrobial agents
 INVENTOR(S): Kro, Helmut; Farrington, Daniel O.; Clark, Jeffrey N.;
 Ratcliffe, Ronald W.; Wilkening, Robert D.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912552	A1	19990318	WO 1998-US18579	19980904
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302010	A1	19990318	CA 1998-2302010	19980904
AU 9893053	A	19990329	AU 1998-93053	19980904
AU 731842	B2	20010405		
EP 1011689	A1	20000628	EP 1998-945912	19980904
EP 1011689	B1	20070131		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
NZ 502861	A	20010330	NZ 1998-502861	19980904
JP 2001515865	T	20010925	JP 2000-510449	19980904
AT 353014	T	20070215	AT 1998-945912	19980904

EP 1779853	A2	20070502	EP 2007-1854	19980904
EP 1779853	A3	20100127		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
ES 2281136	T3	20070916	ES 1998-945912	19980904
US 6339063	B1	20020115	US 2000-508489	20000511

PRIORITY APPLN. INFO.:

US 1997-58330P	P	19970910
GB 1998-6420	A	19980325
EP 1998-945912	A3	19980904
WO 1998-US18579	W	19980904

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 130:218265

IT **97240-71-6** **97276-94-3**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(9a-azalides as veterinary antimicrobial agents)

RN 97240-71-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 97276-94-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 45 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:42572 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 130:81791
TITLE: Preparation of 9a-azalide erythromycin analogs as
bactericides
INVENTOR(S): Blizzard, Timothy A.; Waddell, Sherman T.; Santorelli,
Gina M.; Morgan, Jerry D., II
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9900124	A1	19990107	WO 1998-US12174	19980622
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9879614	A	19990119	AU 1998-79614	19980622
PRIORITY APPLN. INFO.:			US 1997-50810P	P 19970626
			GB 1998-12249	A 19980606
			WO 1998-US12174	W 19980622

OTHER SOURCE(S): MARPAT 130:81791

IT 1097301-86-4 1097301-94-4


RL: PRPH (Prophetic)

(Preparation of 9a-azalide erythromycin analogs as bactericides)

RN 1097301-86-4 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1097301-94-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 46 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:8007 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 130:66726
TITLE: Preparation of C-4''-substituted erythromycin macrolides as antibacterial agents
INVENTOR(S): Bronk, Brian Scott; Kaneko, Takushi; Letavic, Michael Anthony; Cheng, Hengmiao; Glazer, Edward Alan; Yang, Bingwei Vera
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 9856801	A1	19981217	WO 1998-IB799	19980525
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2293397	A1	19981217	CA 1998-2293397	19980525
CA 2293397	C	20040831		
AU 9872281	A	19981230	AU 1998-72281	19980525
AU 745006	B2	20020307		
EP 988309	A1	20000329	EP 1998-919414	19980525
EP 988309	B1	20051123		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810097	A	20000808	BR 1998-10097	19980525
JP 2000514097	T	20001024	JP 1999-501929	19980525
JP 3262806	B2	20020304		
HU 2000004076	A2	20010428	HU 2000-4076	19980525
HU 2000004076	A3	20030528		
NZ 500652	A	20011026	NZ 1998-500652	19980525
IL 132808	A	20040831	IL 1998-132808	19980525
AT 310742	T	20051215	AT 1998-919414	19980525
ES 2251081	T3	20060416	ES 1998-919414	19980525
AP 1189	A	20030716	AP 1998-1254	19980604
W: BW, GM, KE, MW, UG, ZM, ZW				
TW 224106	B	20041121	TW 1998-87109085	19980608
ZA 9805016	A	19991210	ZA 1998-5016	19980610
BG 64357	B1	20041130	BG 1999-103969	19991208
MX 9911496	A	20000731	MX 1999-11496	19991209
NO 9906107	A	20000210	NO 1999-6107	19991210
NO 315560	B1	20030922		
US 6407074	B1	20020618	US 2000-424211	20000216
HK 1025974	A1	20041112	HK 2000-105362	20000828
US 20020156026	A1	20021024	US 2002-84279	20020226
US 6576749	B2	20030610		
PRIORITY APPLN. INFO.:			US 1997-49980P	P 19970611
			WO 1998-IB799	W 19980525
			US 2000-424211	A1 20000216

OTHER SOURCE(S): MARPAT 130:66726


IT 217649-53-1P 217649-54-2P 217649-56-4P
217649-79-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of C-4'''-substituted erythromycin macrolides as antibacterial agents)

RN 217649-53-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[(5R,6S,8R,10R)-10-methoxy-6,10-dimethyl-2-(methylthio)-1,7-dioxo-3-azaspiro[4.5]dec-2-en-8-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 217649-54-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-13-[[(5R,6S,8R,10R)-10-methoxy-6,10-dimethyl-2-(2-thienyl)-1,7-dioxaspiro[4.5]dec-2-en-8-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 217649-56-4 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[[(5R,6S,8R,10R)-2-amino-10-methoxy-6,10-dimethyl-1,7-dioxaspiro[4.5]dec-2-en-8-yl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 217649-79-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[(5R,6S,8R,10R)-10-methoxy-6,10-dimethyl-2-(2-pyridinyl)-1,7-dioxaspiro[4.5]dec-2-en-8-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



IT **92395-24-9**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of C-4'''-substituted erythromycin macrolides as antibacterial agents)

RN 92395-24-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-
 ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-
 [[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 217648-56-1P 217649-48-4P 217649-51-9P
217649-52-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of C-4''-substituted erythromycin macrolides as antibacterial
 agents)


RN 217648-56-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[(3S,4S,6R,8R)-8-methoxy-4,8-dimethyl-1,5-
 dioxaspiro[2.5]oct-6-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-2-O-[(phenylmethoxy)carbonyl]- β -D-xylo-
 hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX
 NAME)

Absolute stereochemistry.




RN 217649-48-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[(3R,4S,6R,8R)-8-methoxy-4,8-dimethyl-1,5-
 dioxaspiro[2.5]oct-6-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 217649-51-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-13-[[(5R,6S,8R,10R)-10-methoxy-6,10-dimethyl-2-
 thioxo-1,7-dioxaspiro[4.5]dec-8-yl]oxy]-3,5,6,8,10,12,14-heptamethyl-
 11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 217649-52-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[(5R,6S,8R,10R)-2-[[2-(3,4-dichlorophenyl)-2-oxoethyl]thio]-10-methoxy-
 6,10-dimethyl-1,7-dioxaspiro[4.5]dec-2-en-8-yl]oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




C1

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
RECORD (12 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 47 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1998:660048 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 129:343641
ORIGINAL REFERENCE NO.: 129:70001a,70004a
TITLE: Synthesis of 6-O-methyl-azithromycin and its ketolide
analog via Beckmann rearrangement of
9(E)-6-O-methyl-erythromycin oxime
AUTHOR(S): Denis, A.; Agouridas, C.
CORPORATE SOURCE: Medicinal Chemistry Dpt., Hoechst Marion Roussel,
Romainville Research Center, Romainville, F-93235, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (1998),
8(18), 2427-2432
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **156885-01-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of 6-O-methyl-azithromycin and its ketolide analog via
Beckmann rearrangement of 9(E)-6-O-methyl-erythromycin oxime)
RN 156885-01-7 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,13-trihydroxy-10-methoxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 48 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1997:472655 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 127:144720
 ORIGINAL REFERENCE NO.: 127:27765a,27768a
 TITLE: Disposition of oral azithromycin in humans
 AUTHOR(S): Luke, David R.; Foulds, George
 CORPORATE SOURCE: Pfizer Central Research, Groton, CT, 06340, USA
 SOURCE: Clinical Pharmacology and Therapeutics (St. Louis) (1997), 61(6), 641-648
 CODEN: CLPTAT; ISSN: 0009-9236
 PUBLISHER: Mosby-Year Book
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT **117693-41-1**
 RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (disposition of oral azithromycin in humans)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L21 ANSWER 49 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:401819 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 125:87051

ORIGINAL REFERENCE NO.: 125:16441a,16444a

TITLE: Synthesis of 3''-Desmethoxyazithromycin:
Regioselectivity and Stereoselectivity of
SmI₂-Mediated α -Deoxygenation Reaction

AUTHOR(S): Yang, Bingwei V.; Massa, Mark A.

CORPORATE SOURCE: Central Research Division, Pfizer Inc., Groton, CT,
06340, USA

SOURCE: Journal of Organic Chemistry (1996), 61(15), 5149-5152
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 125:87051


IT **171661-67-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of desmethoxyazithromycin via regio- and stereoselective SmI₂-mediated α -deoxygenation of azithromycin)

RN 171661-67-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,6S)-
tetrahydro-4,6-dimethyl-5-oxo-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



IT **171661-68-0P 171865-16-0P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of desmethoxyazithromycin via regio- and stereoselective
SmI2-mediated α -deoxygenation of azithromycin)

RN 171661-68-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,5R,6S)-
tetrahydro-5-hydroxy-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 171865-16-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,5S,6S)-
tetrahydro-5-hydroxy-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




IT **92395-24-9**

RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of desmethoxyazithromycin via regio- and stereoselective
SmI2-mediated α -deoxygenation of azithromycin)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-
ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-
[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **92395-23-8P** **171661-78-2P** **178456-39-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of desmethoxyazithromycin via regio- and stereoselective
SmI2-mediated α -deoxygenation of azithromycin)

RN 92395-23-8 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 171661-78-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 13-[(tetrahydro-4,6-dimethyl-5-oxo-2H-pyran-2-yl)oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,6S*),14R*]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 178456-39-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-
 hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 13-[(tetrahydro-4,6-dimethyl-5-oxo-2H-pyran-2-yl)oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4S*,6S*),14R*]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



IT **178456-40-1P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of desmethoxyazithromycin via regio- and stereoselective
SmI2-mediated α -deoxygenation of azithromycin)

RN 178456-40-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[(tetrahydro-4,6-
dimethyl-5-oxo-2H-pyran-2-yl)oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)-
 β -D-xylo-hexopyranosyl]oxy]-,
[2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4S*,6S*),14R*]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

L21 ANSWER 50 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1996:87420 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 124:193184
ORIGINAL REFERENCE NO.: 124:35403a,35406a
TITLE: Pharmacokinetic study of azithromycin in experimental animals
AUTHOR(S): Muto, Hideya; Kuboe, Yuka; Kimura, Yasuko; Saito, Susumu; Sekiguchi, Kaneo; Enogaki, Kazunori; Shimooka, Kino
CORPORATE SOURCE: New Prod. Dev. Cent., Pfizer Pharm. Inc., Aichi, 470-23, Japan
SOURCE: Nippon Kagaku Ryoho Gakkai Zasshi (1995), 43(Suppl. 6), 110-21
CODEN: NKRZE5; ISSN: 1340-7007
DOCUMENT TYPE: Journal
LANGUAGE: Japanese


IT **117693-41-1**

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(metabolite; azithromycin pharmacokinetics, metabolism, and protein binding)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 51 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1996:87419 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 124:249473
ORIGINAL REFERENCE NO.: 124:45861a,45864a
TITLE: Method of measuring azithromycin concentration in body fluid by bioassay and high-performance liquid chromatography
AUTHOR(S): Sawada, Yasufusa; Muto, Hideya; Enogaki, Kazunori; Shimooka, Kino
CORPORATE SOURCE: New Prod. Dev. Cent., Pfizer Pharm. Inc., Aichi, 470-23, Japan
SOURCE: Nippon Kagaku Ryoho Gakkai Zasshi (1995), 43(Suppl. 6), 100-9

CODEN: NKRZE5; ISSN: 1340-7007

DOCUMENT TYPE: Journal
LANGUAGE: Japanese

IT **117693-41-1**


RL: ANT (Analyte); BSU (Biological study, unclassified); MFM (Metabolic formation); ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative)

(metabolite; determination of azithromycin and its metabolites in body fluid by bioassay and HPLC)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 52 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:912607 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 124:75436

ORIGINAL REFERENCE NO.: 124:13765a,13768a

TITLE: Azithromycin concentrations in gallbladder, hepatic tissue, and bile following a 5-day regimen in humans
AUTHOR(S): Foulds, G.; Ferraina, R. A.; Fouda, H. G.; Johnson, R. B.; Kamel, A. M.; Shepard, R. M.; Falcone, R.; Hanna, C.

CORPORATE SOURCE: Pfizer Inc., Groton, CT, USA

SOURCE: Infectious Disease and Therapy (1995), 18(New Macrolides, Azalides, and Streptogramins in Clinical Practice), 367-72

CODEN: IDTHER; ISSN: 1043-2981

PUBLISHER: Dekker

DOCUMENT TYPE: Journal

LANGUAGE: English


IT **117693-41-1**, CP 66458

RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(presence of azithromycin metabolites in human bile)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)

L21 ANSWER 53 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:795404 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 124:56562

ORIGINAL REFERENCE NO.: 124:10713a,10716a

TITLE: Preparation of 3''-desmethoxy derivatives of
 erythromycin and azithromycin as antibacterial agents

INVENTOR(S): Yang, Bingwei V.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 10 pp.
 CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5441939	A	19950815	US 1994-206551	19940304
CA 2184734	A1	19950908	CA 1995-2184734	19950202
CA 2184734	C	19990803		
WO 9523808	A1	19950908	WO 1995-IB74	19950202
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 748329	A1	19961218	EP 1995-906455	19950202
EP 748329	B1	19990707		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09511498	T	19971118	JP 1995-522795	19950202
JP 3083102	B2	20000904		
AT 181923	T	19990715	AT 1995-906455	19950202
ES 2133175	T3	19990901	ES 1995-906455	19950202
FI 9501003	A	19950905	FI 1995-1003	19950303

FI 110780 B1 20030331
 PRIORITY APPLN. INFO.: US 1994-206551 A 19940304
 WO 1995-IB74 W 19950202

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 124:56562; MARPAT 124:56562


IT 171661-67-9P 171661-68-0P 171661-69-1P
171661-70-4P 171661-71-5P 171661-77-1P
171865-16-0P 171865-17-1P 171865-19-3P
171865-23-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3''-desmethoxy derivs. of erythromycin and azithromycin as antibacterial agents)

RN 171661-67-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,6S)-
 tetrahydro-4,6-dimethyl-5-oxo-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 171661-68-0 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,5R,6S)-
 tetrahydro-5-hydroxy-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 171661-69-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[tetrahydro-4-(hydroxyimino)-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,6S*),14R*]]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.




RN 171661-70-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(5-aminotetrahydro-4,6-dimethyl-2H-pyran-2-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,5R*,6S*),14R*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171661-71-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[(tetrahydro-5-
 hydroxy-4,5,6-trimethyl-2H-pyran-2-yl)oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,5R*,6S*),14R*]]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171661-77-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[(tetrahydro-5-
 hydroxy-4,6-dimethyl-5-phenyl-2H-pyran-2-yl)oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,5R*,6S*),14R*]]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 171865-16-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[[(2R,4R,5S,6S)-
 tetrahydro-5-hydroxy-4,6-dimethyl-2H-pyran-2-yl]oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 171865-17-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[(tetrahydro-5-
 hydroxy-4,5,6-trimethyl-2H-pyran-2-yl)oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,5S*,6S*),14R*]]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171865-19-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(5-aminotetrahydro-4,6-dimethyl-2H-pyran-2-yl)oxy]-2-ethyl-3,4,10-
 trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,5S*,6S*),14R*]]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171865-23-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-13-[(tetrahydro-5-
 hydroxy-4,6-dimethyl-5-phenyl-2H-pyran-2-yl)oxy]-11-[[3,4,6-trideoxy-3-
 (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,5S*,6S*),14R*]]-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **92395-23-8**


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 3'''-desmethoxy derivs. of erythromycin and azithromycin as antibacterial agents)

RN 92395-23-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT **171661-78-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation of 3'''-desmethoxy derivs. of erythromycin and azithromycin as antibacterial agents)

RN 171661-78-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
13-[(tetrahydro-4,6-dimethyl-5-oxo-2H-pyran-2-yl)oxy]-,
[2R-[2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*(2R*,4R*,6S*),14R*]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS
RECORD (11 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 54 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:534695 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 121:134695

ORIGINAL REFERENCE NO.: 121:24381a,24384a

TITLE: preparation of new
11-(glycosyloxy)-1-oxa-6-azacyclopentadecane-13,15-
dione derivatives having antibiotic activity.

INVENTOR(S): Agouridas, Constantin; Chantot, Jean Francois; Denis,
Alexis; Le Martret, Odile

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.

SOURCE: Fr. Demande, 17 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2691464	A1	19931126	FR 1992-6173	19920521
FR 2691464	B1	19950602		

PRIORITY APPLN. INFO.:

FR 1992-6173

19920521

OTHER SOURCE(S):

CASREACT 121:134695; MARPAT 121:134695


IT **156885-01-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of)

RN 156885-01-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-2-ethyl-3,4,13-trihydroxy-10-methoxy-3,5,6,8,10,12,14-
heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




IT **156885-00-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and O-acetylation of)

RN 156885-00-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,13-trihydroxy-10-methoxy-3,5,6,8,10,12,14-heptamethyl-11-
[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
[2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX
NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 55 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:77599 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 120:77599
ORIGINAL REFERENCE NO.: 120:13977a,13980a
TITLE: Preparation of 5-O-desosaminylerythronolide
derivatives as antibacterial agents
INVENTOR(S): Asaka, Toshifumi; Misawa, Yoko; Kashimura, Masato;
Morimoto, Shigeo; Hatayama, Katsuo
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9313116	A1	19930708	WO 1992-JP1714	19921225
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9331728	A	19930728	AU 1993-31728	19921225
AU 667334	B2	19960321		
EP 619320	A1	19941012	EP 1993-900447	19921225
EP 619320	B1	19970521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 149508	T	19970315	AT 1993-900446	19921225
AT 153341	T	19970615	AT 1993-900447	19921225
ES 2101290	T3	19970701	ES 1993-900446	19921225
ES 2104118	T3	19971001	ES 1993-900447	19921225
JP 3132002	B2	20010205	JP 1993-511558	19921225
US 5631354	A	19970520	US 1994-256124	19940621
PRIORITY APPLN. INFO.:			JP 1991-346826	A 19911227
			JP 1992-199368	A 19920727
			JP 1992-279867	A 19921019
			WO 1992-JP1714	A 19921225

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 120:77599


IT **152234-74-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as antibacterial agent)


RN 152234-74-7 CAPLUS

CN Benzeneacetic acid, 4-nitro-, 2-ethyl-3,4-dihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylohexopyranosyl]oxy]-1-oxa-6-azacyclopentadecane-10,13-diyl ester, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




IT **117693-41-1P 152235-41-1P 152235-42-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate for desosaminylerythronolide antibacterial agent)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 152235-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 152235-42-2 CAPLUS

CN Benzeneacetic acid, 4-nitro-, 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-2-ethyl-3,4-dihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadecane-10,13-diyl ester, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (43 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 56 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:15318 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 114:15318


ORIGINAL REFERENCE NO.: 114:2619a,2622a

TITLE: Structure of 10,10-dihydro-10-deoxo-10a-methyl-10a-aza-10a-homoerythronolide A

AUTHOR(S): Kamenar, Boris; Mrvos-Sermek, Draginja; Vickovic,

Ivan; Nagl, Ante
 CORPORATE SOURCE: Fac. Sci., Univ. Zagreb, Zagreb, 41001, Yugoslavia
 SOURCE: Acta Crystallographica, Section C: Crystal Structure
 Communications (1990), C46(10), 1964-6
 CODEN: ACSCEE; ISSN: 0108-2701
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT **117693-42-2**
 RL: PRP (Properties)
 (crystal structure of)
 RN 117693-42-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 57 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1990:631098 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 113:231098
 ORIGINAL REFERENCE NO.: 113:38989a,38992a
 TITLE: Preparation of 9-deoxy-9a-azahomoerythronolide A
 derivatives as antiinflammatories
 INVENTOR(S): Djokic, Slobodan; Lopotar, Nevenka; Krnjevic,
 Gabrijela Kobrenel, H.; Carevic, Olga; Carevic, Olga
 PATENT ASSIGNEE(S): SOUR PLIVA Farmaceutska, Kemijska, Prehrambena i
 Kozmeticka Industrija n.sol.o., Yugoslavia
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 23 pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
CN 1031703	A	19890315	CN 1988-103197	19880520
CN 1020452	C	19930505		
HU 47552	A2	19890328	HU 1988-1778	19880408
HU 198913	B	19891228		
US 4886792	A	19891212	US 1988-180491	19880412
DD 272647	A5	19891018	DD 1988-314705	19880413
CS 274462	B2	19910411	CS 1988-2533	19880413
CA 1296000	C	19920218	CA 1988-564025	19880413

RO 101119	B1	19920528	RO 1988-133069	19880414
RO 105811	B1	19921230	RO 1988-144712	19880414
PL 155159	B1	19911031	PL 1988-272025	19880422
RU 2007398	C1	19940215	RU 1988-4355672	19880516
JP 01287076	A	19891117	JP 1988-180450	19880721
CS 274497	B2	19910411	CS 1989-1816	19890323
PRIORITY APPLN. INFO.:			YU 1987-1631	A 19870903
			YU 1988-85	A 19880118
			CS 1988-2533	A3 19880413

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 113:231098


IT **117693-42-2P** **118382-93-7P** **118382-94-8P**
118456-11-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory)

RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 118382-93-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-(acetyloxy)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-,
[2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12R*,13S*,14R*)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 118382-94-8 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
3,11,13-tris(acetyloxy)-2-ethyl-4,10-dihydroxy-3,5,6,8,10,12,14-
heptamethyl-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 118456-11-4 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
hydrochloride, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

L21 ANSWER 58 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1990:185654 CAPLUS <<LOGINID::20100317>>
DOCUMENT NUMBER: 112:185654
ORIGINAL REFERENCE NO.: 112:31273a,31276a
TITLE: Comparison of the acid stability of azithromycin and erythromycin A
AUTHOR(S): Fiese, E. F.; Steffen, S. H.
CORPORATE SOURCE: Cent. Res. Div., Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Journal of Antimicrobial Chemotherapy (1990), 25(Suppl. A), 39-47
CODEN: JACHDX; ISSN: 0305-7453
DOCUMENT TYPE: Journal

LANGUAGE: English
 IT **117693-41-1**, CP 66458
 RL: FORM (Formation, nonpreparative)
 (formation of, as azithromycin degradation product)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS
 RECORD (14 CITINGS)

L21 ANSWER 59 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1990:62626 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 112:62626
 ORIGINAL REFERENCE NO.: 112:10623a,10626a
 TITLE: Antiprotozoal pharmaceuticals containing azithromycin
 and derivatives
 INVENTOR(S): Remington, Jack Samuel
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 7 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 307128	A2	19890315	EP 1988-308024	19880831
EP 307128	A3	19900704		
EP 307128	B1	19920408		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
WO 8902271	A1	19890323	WO 1987-US2317	19870910
W: AU, DK, JP, US				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AU 8782800	A	19890417	AU 1987-82800	19870910
US 4963531	A	19901016	US 1988-359676	19880816

AT 74508	T	19920415	AT 1988-308024	19880831
IL 87698	A	19921201	IL 1988-87698	19880907
CA 1334574	C	19950228	CA 1988-576732	19880908
DK 8805028	A	19890313	DK 1988-5028	19880909
DK 175544	B1	20041129		
HU 47553	A2	19890328	HU 1988-4667	19880909
AU 8822061	A	19890511	AU 1988-22061	19880909
AU 596029	B2	19900412		
ZA 8806727	A	19900425	ZA 1988-6727	19880909
JP 02083326	A	19900323	JP 1988-227353	19880910
JP 06067847	B	19940831		
PRIORITY APPLN. INFO.:			WO 1987-US2317	A 19870910
			EP 1988-308024	A 19880831


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT **124794-69-0** **124794-70-3** **124916-84-3**

RL: BIOL (Biological study)
(antiprotozoal agent)


RN 124794-69-0 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2-deoxy-3-C-methyl-3-O-methyl- β -D-threo-pentopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




RN 124794-70-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-pentopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)



RN 124916-84-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(4-amino-2,4-dideoxy-3-C-methyl-3-O-methyl-β-D-threo-
 pentopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-,
 [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX
 NAME)




OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS
 RECORD (18 CITINGS)

L21 ANSWER 60 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1989:154752 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 110:154752
 ORIGINAL REFERENCE NO.: 110:25611a,25614a
 TITLE: Synthesis, in vitro and in vivo activity of novel
 9-deoxo-9a-aza-9a-homoerythromycin A derivatives; a
 new class of macrolide antibiotics, the azalides
 AUTHOR(S): Bright, G. Michael; Nagel, Arthur A.; Bordner, Jon;
 Desai, Kishor A.; Dibrino, Joseph N.; Nowakowska,

Jolanta; Vincent, Lawrence; Watrous, Richard M.;
 Sciavolino, Frank C.; et al.
 CORPORATE SOURCE: Med. Chem. Dep., Pfizer Inc., Groton, CT, 06340, USA
 SOURCE: Journal of Antibiotics (1988), 41(8), 1029-47
 CODEN: JANTAJ; ISSN: 0021-8820
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 110:154752


IT **97240-71-6P** **97240-76-1P**
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and antibiotic spectrum of)
 RN 97240-71-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
 11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 97240-76-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 (hydroxyimino)-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry unknown.



IT **92395-23-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and deacetylation of)

RN 92395-23-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT **92395-24-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reactions of)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-

ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-
[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 78 THERE ARE 78 CAPLUS RECORDS THAT CITE THIS
RECORD (79 CITINGS)

L21 ANSWER 61 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:141630 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 110:141630

ORIGINAL REFERENCE NO.: 110:23269a,23272a

TITLE: Reversed-phase HPLC analysis of the semisynthetic
macrolide antibiotic azithromycin

AUTHOR(S): Kovacic-Bosnjak, N.; Marincel, J.; Lopotar, N.;
Kobrehel, G.

CORPORATE SOURCE: Pliva, Res. Inst. Pharm., Chem., Food Cosmet. Ind.,
Zagreb, 41000, Yugoslavia

SOURCE: Chromatographia (1988), 25(11), 999-1003
CODEN: CHRGB7; ISSN: 0009-5893

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 117693-41-1 117693-42-2

RL: ANST (Analytical study)
(azithromycin separation from, by HPLC)

RN 117693-41-1 CAPLUS


CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 117693-42-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS
 RECORD (10 CITINGS)

L21 ANSWER 62 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1989:57417 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 110:57417
 ORIGINAL REFERENCE NO.: 110:9493a,9496a
 TITLE: 10-Dihydro-10-deoxo-11-azaerythronolide A derivatives
 as antiinflammatory agents and their preparation
 INVENTOR(S): Djokic, Slobodan; Lopotar, Nevenka; Kobrehel,
 Gabrijela; Krnjevic, Hrvoje; Carevic, Olga
 PATENT ASSIGNEE(S): SOUR PLIVA Farmaceutska, Kemijska, Prehrambena i
 Kozmeticka Industrija n.sol.o., Yugoslavia
 SOURCE: Eur. Pat. Appl., 16 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 283055	A2	19880921	EP 1988-105626	19880408
EP 283055	A3	19890315		
EP 283055	B1	19900829		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 47552	A2	19890328	HU 1988-1778	19880408
HU 198913	B	19891228		
AT 55999	T	19900915	AT 1988-105626	19880408
US 4886792	A	19891212	US 1988-180491	19880412
DD 272647	A5	19891018	DD 1988-314705	19880413
CS 274462	B2	19910411	CS 1988-2533	19880413
CA 1296000	C	19920218	CA 1988-564025	19880413
RO 101119	B1	19920528	RO 1988-133069	19880414
RO 105811	B1	19921230	RO 1988-144712	19880414
PL 155159	B1	19911031	PL 1988-272025	19880422
RU 2007398	C1	19940215	RU 1988-4355672	19880516
JP 01287076	A	19891117	JP 1988-180450	19880721
CS 274497	B2	19910411	CS 1989-1816	19890323
PRIORITY APPLN. INFO.:			YU 1987-1631	A 19870903
			YU 1988-85	A 19880118
			EP 1988-105626	A 19880408
			CS 1988-2533	A3 19880413

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 110:57417


IT 117693-41-1P 118382-93-7P 118382-94-8P
118456-11-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)

RN 117693-41-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 118382-93-7 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-(acetyloxy)-2-ethyl-3,4,10,11-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-
, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12R*,13S*,14R*)]- (9CI) (CA INDEX

NAME)


Absolute stereochemistry.



RN 118382-94-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
3,11,13-tris(acetyloxy)-2-ethyl-4,10-dihydroxy-3,5,6,8,10,12,14-
heptamethyl-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 118456-11-4 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
hydrochloride, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT **117693-42-2**

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antiinflammatory agent)

RN 117693-42-2 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

L21 ANSWER 63 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1989:8535 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 110:8535

ORIGINAL REFERENCE NO.: 110:1571a,1574a

TITLE: Erythromycin series. Part 13. Synthesis and structure elucidation of 10-dihydro-10-deoxo-11-methyl-11-azaerythromycin A
AUTHOR(S): Djokic, Slobodan; Kobrehel, Gabrijela; Lopotar, Nevenka; Kamenar, Boris; Nagl, Ante; Mrvos, Draginja
CORPORATE SOURCE: Pharm., Chem., Food Cosmet. Ind., Res. Inst., PLIVA, Zagreb, 41001, Yugoslavia


SOURCE: Journal of Chemical Research, Synopses (1988), (5), 152-3

CODEN: JRPSDC; ISSN: 0308-2342

DOCUMENT TYPE: Journal


LANGUAGE: English
 OTHER SOURCE(S): CASREACT 110:8535
 IT **117693-41-1P 117693-42-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 117693-41-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,13-tetrahydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-
 trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 117693-42-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10,11,13-pentahydroxy-3,5,6,8,10,12,14-heptamethyl-,
 (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS
 RECORD (15 CITINGS)

L21 ANSWER 64 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1985:615726 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 103:215726
 ORIGINAL REFERENCE NO.: 103:34791a,34794a

TITLE: 9 α -Aza-9 α -homoerythromycin compounds and
 their therapeutic use
 INVENTOR(S): Hauske, James R.; Nagel, Arthur A.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S., 16 pp. Cont.-in-part of U.S. Ser. No. 600,252.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4518590	A	19850521	US 1984-616529	19840604
US 4512982	A	19850423	US 1984-600252	19840413
EP 159856	A2	19851030	EP 1985-302507	19850410
EP 159856	A3	19860319		
EP 159856	B1	19880928		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
IL 74865	A	19871231	IL 1985-74865	19850410
AT 37550	T	19881015	AT 1985-302507	19850410
FI 8501449	A	19851014	FI 1985-1449	19850411
CA 1234805	A1	19880405	CA 1985-478792	19850411
NO 8501466	A	19851014	NO 1985-1466	19850412
NO 161497	B	19890516		
NO 161497	C	19890823		
AU 8541070	A	19851017	AU 1985-41070	19850412
AU 549235	B2	19860123		
DK 8501647	A	19851210	DK 1985-1647	19850412
HU 37629	A2	19860123	HU 1985-1370	19850412
HU 195668	B	19880628		
JP 60231691	A	19851118	JP 1985-79136	19850413
PRIORITY APPLN. INFO.:			US 1984-600252	A2 19840413
			US 1984-616529	A 19840604
			EP 1985-302507	A 19850410

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 103:215726

IT **97240-76-1P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrogenation of)

RN 97240-76-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 (hydroxyimino)-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranosyl]oxy]-
 , (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




IT **97240-74-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrogenolysis of)

RN 97240-74-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-methyl-3-O-methyl-4-[(phenylmethoxy)carbonyl]amino]-α-L-xylo-hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)



IT **92395-24-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and reductive amination of)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-

[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT	<u>97240-71-6P</u>	<u>97276-94-3P</u>	<u>98401-67-3P</u>
	<u>98401-68-4P</u>	<u>98401-69-5P</u>	<u>98401-70-8P</u>
	<u>98401-71-9P</u>	<u>98401-72-0P</u>	<u>98401-73-1P</u>
	<u>98401-74-2P</u>	<u>98401-75-3P</u>	<u>98401-76-4P</u>
	<u>98401-77-5P</u>	<u>98401-78-6P</u>	<u>98401-79-7P</u>
	<u>98401-80-0P</u>	<u>98401-81-1P</u>	<u>98401-82-2P</u>
	<u>98401-83-3P</u>	<u>98401-84-4P</u>	<u>98401-85-5P</u>
	<u>98401-86-6P</u>	<u>98401-87-7P</u>	<u>98401-88-8P</u>
	<u>98401-89-9P</u>	<u>98401-90-2P</u>	<u>98401-91-3P</u>
	<u>98401-92-4P</u>	<u>98401-93-5P</u>	<u>98401-94-6P</u>
	<u>98401-95-7P</u>	<u>98401-96-8P</u>	<u>98401-97-9P</u>
	<u>98401-98-0P</u>	<u>98401-99-1P</u>	<u>98464-18-7P</u>
	<u>98464-19-8P</u>		

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 97240-71-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-(CA INDEX NAME)


Absolute stereochemistry.



RN 97276-94-3 CAPLUS



CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 98401-67-3 CAPLUS



CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[[4-[[[(4-chlorophenyl)sulfonyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-
methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
D-xylo-hexopyranosyl]oxy]-, [2R-
(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




RN 98401-68-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [[(4-iodophenyl)sulfonyl]amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-69-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(3-fluorobenzoyl)amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)






RN 98401-70-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(3,3-dimethyl-1-oxobutyl)amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)





RN 98401-71-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(1-oxooctyl)amino]-α-L-xylo-hexopyranosyl]oxy]-
 , [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-(9CI) (CA INDEX
 NAME)





RN 98401-72-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [[(4-fluorophenyl)acetyl]amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-(
 9CI) (CA INDEX NAME)




RN 98401-73-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[[[2-(trifluoromethyl)phenyl]acetyl]amino]- α -L-
 xylo-hexopyranosyl]oxy]-, [2R-
 (2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)



RN 98401-74-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(4-methoxybenzoyl)amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)





RN 98401-75-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(2-thienylsulfonyl)amino]-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-76-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(2-furanylcarbonyl)amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)

PAGE 1-A









RN 98401-77-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(1-oxo-3-phenylpropyl)amino]- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-78-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[(2-chlorobenzoyl)amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl-
 α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, [2R-
 (2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




RN 98401-79-7 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(2-fluorobenzoyl)amino]-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)



RN 98401-80-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(phenylacetyl)amino]- α -L-ribo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-81-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-[(2,2-dimethyl-1-oxopropyl)amino]-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




RN 98401-82-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[(3-chlorobenzoyl)amino]-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, [2R-

(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A



RN 98401-83-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[[(4-chlorophenoxy)acetyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-
 methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, [2R-
 (2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




RN 98401-84-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(phenoxyacetyl)amino]- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)





RN 98401-85-5 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(4-fluorobenzoyl)amino]-3-C-methyl-3-O-methyl-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)

PAGE 1-A



|
F


RN 98401-86-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(pyrazinylcarbonyl)amino]- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-87-7 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-

[[(4-methoxyphenyl) acetyl] amino] -3-C-methyl-3-O-methyl- α -L-xylo-
hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
(9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A



RN 98401-88-8 CAPLUS
CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
methyl-3-O-methyl-4-[(2-pyridinylcarbonyl) amino]- α -L-xylo-
hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
(9CI) (CA INDEX NAME)






RN 98401-89-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(1-oxo-4-phenylbutyl)amino]-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-90-2 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(3-thienylacetyl)amino]- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)


PAGE 1-A







RN 98401-91-3 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [[(2-fluorophenyl)acetyl]amino]-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)






RN 98401-92-4 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [(3-isoxazolylcarbonyl)amino]-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)





RN 98401-93-5 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [[(3-fluorophenyl)acetyl]amino]-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 98401-94-6 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[[(2-chlorophenyl)acetyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-

methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, [2R-
 (2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)



PAGE 1-A






PAGE 2-A





RN 98401-95-7 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[[(3-chlorophenyl)acetyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-
 methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, [2R-
 (2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)






RN 98401-96-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[[4-[[[(4-chlorophenyl)acetyl]amino]-2,4,6-trideoxy-3-C-methyl-3-O-
 methyl- α -L-xylo-hexopyranosyl]oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -
 D-xylo-hexopyranosyl]oxy]-, [2R-
 (2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)





RN 98401-97-9 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
 [[(4-hydroxyphenyl)acetyl]amino]-3-C-methyl-3-O-methyl- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)




RN 98401-98-0 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[[(4-nitrophenyl) acetyl] amino]- α -L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)



RN 98401-99-1 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(phenylsulfonyl)amino]-α-L-xylo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)





RN 98464-18-7 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[[(phenylmethoxy) carbonyl] amino]- α -L-ribo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)



RN 98464-19-8 CAPLUS
 CN 1-Oxa-6-azacyclopentadecan-15-one,
 2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
 3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-
 methyl-3-O-methyl-4-[(phenylsulfonyl)amino]- α -L-ribo-
 hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]-
 (9CI) (CA INDEX NAME)

PAGE 1-A




IT **92395-23-8**RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with hydroxylamine)

RN 92395-23-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-
3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 65 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1985:488173 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 103:88173

ORIGINAL REFERENCE NO.: 103:14177a,14180a

TITLE: Azahomoerythromycin B derivatives and their
intermediates

INVENTOR(S): Bright, Gene Michael; Hauske, James Robert
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 21 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 136831	A2	19850410	EP 1984-306009	19840903
EP 136831	A3	19860319		
EP 136831	B1	19881109		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 38519	T	19881115	AT 1984-306009	19840903
CA 1239398	A1	19880719	CA 1984-462343	19840904
DK 8404230	A	19850307	DK 1984-4230	19840905
DK 159450	B	19901015		
DK 159450	C	19910318		
JP 60072896	A	19850424	JP 1984-187244	19840906
PRIORITY APPLN. INFO.:			US 1983-529827	A 19830906
			EP 1984-306009	A 19840903

OTHER SOURCE(S): MARPAT 103:88173


IT **92395-23-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deacetylation of)

RN 92395-23-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
 erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-
 3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



IT **92395-24-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation and hydrogenation of)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L21 ANSWER 66 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1985:454407 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 103:54407

ORIGINAL REFERENCE NO.: 103:8781a,8784a

TITLE: 9A-Aza-9a-homoerythromycin compounds, pharmaceutical composition and therapeutic method

INVENTOR(S): Hauske, James R.; Nagel, Arthur A.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 10 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4512982	A	19850423	US 1984-600252	19840413
US 4518590	A	19850521	US 1984-616529	19840604
EP 159856	A2	19851030	EP 1985-302507	19850410
EP 159856	A3	19860319		
EP 159856	B1	19880928		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
IL 74865	A	19871231	IL 1985-74865	19850410
AT 37550	T	19881015	AT 1985-302507	19850410
FI 8501449	A	19851014	FI 1985-1449	19850411

CA 1234805	A1	19880405	CA 1985-478792	19850411
NO 8501466	A	19851014	NO 1985-1466	19850412
NO 161497	B	19890516		
NO 161497	C	19890823		
AU 8541070	A	19851017	AU 1985-41070	19850412
AU 549235	B2	19860123		
DK 8501647	A	19851210	DK 1985-1647	19850412
HU 37629	A2	19860123	HU 1985-1370	19850412
HU 195668	B	19880628		
DD 234010	A5	19860319	DD 1985-275145	19850412
ZA 8502739	A	19861126	ZA 1985-2739	19850412
PL 144283	B1	19880531	PL 1985-252904	19850412
PL 144330	B1	19880531	PL 1985-256444	19850412
PL 144946	B1	19880730	PL 1985-256443	19850412
JP 60231691	A	19851118	JP 1985-79136	19850413
CN 85103264	A	19870114	CN 1985-103264	19850427
PRIORITY APPLN. INFO.:			US 1984-600252	A2 19840413
			US 1984-616529	A 19840604
			EP 1985-302507	A 19850410

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 103:54407


IT **97240-76-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and catalytic hydrogenation of)

RN 97240-76-1 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-
3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-4-
(hydroxyimino)-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranosyl]oxy]-
, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT **92395-24-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyanoborohydride reduction of)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **92395-23-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deacetylation and oximation of)

RN 92395-23-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




IT **97240-74-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)

RN 97240-74-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-13-[[2,4,6-trideoxy-3-C-methyl-3-O-methyl-4-[[(phenylmethoxy) carbonyl] amino]- α -L-xylo-hexopyranosyl]oxy]-, [2R-(2R*,3S*,4R*,5R*,8R*,10R*,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)




IT **97240-71-6P 97276-94-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 97240-71-6 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-xylo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 97276-94-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(4-amino-2,4,6-trideoxy-3-C-methyl-3-O-methyl- α -L-ribo-
hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-
11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 67 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1984:630951 CAPLUS <<LOGINID::20100317>>

DOCUMENT NUMBER: 101:230951

ORIGINAL REFERENCE NO.: 101:35089a,35092a

TITLE: Azahomoerythromycin D derivative and its intermediates

INVENTOR(S): Bright, Gene M.; Hauske, James R.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S., 8 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4465674	A	19840814	US 1983-529828	19830906
EP 136830	A2	19850410	EP 1984-306008	19840903
EP 136830	A3	19860319		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1240320	A1	19880809	CA 1984-462342	19840904
DK 8404231	A	19850307	DK 1984-4231	19840905
DK 157877	B	19900226		
DK 157877	C	19900723		
JP 60072897	A	19850424	JP 1984-187243	19840906
PRIORITY APPLN. INFO.:			US 1983-529828	A 19830906


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 101:230951

IT **92885-77-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antibacterial activity of)

RN 92885-77-3 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 13-[(2,6-dideoxy-3-C-methyl- α -L-ribo-hexopyranosyl)oxy]-2-ethyl-4,10-dihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
 [2R-(2R*,3R*,4S*,5R*,8R*,10R,11R*,12S*,13S*,14R*)]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 68 OF 68 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:611651 CAPLUS <<LOGINID::20100317>>
 DOCUMENT NUMBER: 101:211651
 ORIGINAL REFERENCE NO.: 101:32087a,32090a

TITLE: Epimeric azahomoerythromycin A derivative and its intermediates
 INVENTOR(S): Bright, Gene Michael
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: Eur. Pat. Appl., 35 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 109253	A2	19840523	EP 1983-306815	19831109
EP 109253	A3	19840912		
EP 109253	B1	19871014		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 30237	T	19871015	AT 1983-306815	19831109
CA 1239639	A1	19880726	CA 1983-440924	19831110
DK 8305186	A	19840516	DK 1983-5186	19831114
DK 159322	B	19901001		
DK 159322	C	19910225		
FI 8304163	A	19840516	FI 1983-4163	19831114
FI 72980	B	19870430		
FI 72980	C	19870810		
NO 8304146	A	19840516	NO 1983-4146	19831114
NO 160262	B	19881219		
NO 160262	C	19890329		
AU 8321309	A	19840524	AU 1983-21309	19831114
AU 544790	B2	19850613		
DD 216017	A5	19841128	DD 1983-256672	19831114
ZA 8308460	A	19850626	ZA 1983-8460	19831114
HU 35273	A2	19850628	HU 1983-3902	19831114
HU 193886	B	19871228		
SU 1272996	A3	19861123	SU 1983-3661803	19831114
IL 70228	A	19870331	IL 1983-70228	19831114
PL 142601	B1	19871130	PL 1983-250350	19831114
PL 143281	B1	19880130	PL 1983-244557	19831114
JP 59104398	A	19840616	JP 1983-214928	19831115
JP 01040038	B	19890824		
CS 241069	B2	19860313	CS 1983-8455	19831115
US 4526889	A	19850702	US 1984-601185	19840417
CS 241099	B2	19860313	CS 1984-7926	19841018
CA 1250284	A2	19890221	CA 1988-562041	19880321
PRIORITY APPLN. INFO.:			US 1982-441979	A 19821115
			EP 1983-306815	A 19831109
			CA 1983-440924	A3 19831110
			CS 1983-8455	A3 19831115

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 101:211651

IT **92395-23-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and deacetylation of)

RN 92395-23-8 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
 11-[[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-
 hexopyranosyl]oxy]-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-
 erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-

3,5,6,8,10,12,14-heptamethyl-, (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




IT **92395-24-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and hydrogenation of)

RN 92395-24-9 CAPLUS

CN 1-Oxa-6-azacyclopentadecan-15-one,
13-[(2,6-dideoxy-3-C-methyl-3-O-methyl- α -L-erythro-hexopyranos-4-ulos-1-yl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)- β -D-xylo-hexopyranosyl]oxy]-,
(2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS
RECORD (12 CITINGS)

```
=> azithromycin and angolosamine
      5234 AZITHROMYCIN
        7 AZITHROMYCINS
      5235 AZITHROMYCIN
        (AZITHROMYCIN OR AZITHROMYCINS)
        9 ANGOLOSAMINE
L22      1 AZITHROMYCIN AND ANGOLOSAMINE
```

=> d

```
L22  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2010 ACS on STN
AN   2005:523474  CAPLUS <<LOGINID::20100317>>
DN   143:58589
TI   Manufacture of erythromycin and azithromycin analogs with
      altered C-5 glycosylation using polyketide synthases with foreign
      glycosyltransferase domains
IN   Kendrew, Steven Gary; Lill, Rachel Elizabeth
PA   Biotica Technology Limited, UK; Pfizer Inc.; Gaisser, Sabine
SO   PCT Int. Appl., 119 pp.
      CODEN: PIXXD2
```

```
DT   Patent
LA   English
```

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005054265	A2	20050616	WO 2004-GB5001	20041129
	WO 2005054265	A3	20050825		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,				
	SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
	NE, SN, TD, TG				
	CA 2547560	A1	20050616	CA 2004-2547560	20041129
	BR 2004017026	A	20070206	BR 2004-17026	20041129
	EP 1749101	A2	20070207	EP 2004-798692	20041129
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2007512013	T	20070517	JP 2006-540616	20041129
	MX 2006006022	A	20060823	MX 2006-6022	20060526
	US 20080044860	A1	20080221	US 2007-580872	20070611
PRAI	GB 2003-27721	A	20031128		
	WO 2004-GB5001	W	20041129		

```
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 143:58589
```

```
OSC.G  1      THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT  5      THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
          ALL CITATIONS AVAILABLE IN THE RE FORMAT
```